[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 490
1. Jansen SA, Paunesku T, Fan X, Woloschak GE, Vogt S, Conzen SD, Krausz T, Newstead GM, Karczmar GS: Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model. Radiology; 2009 Nov;253(2):399-406
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model.
  • PURPOSE: To combine dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging with x-ray fluorescence microscopy (XFM) of mammary gland tissue samples from mice to identify the spatial distribution of gadolinium after intravenous injection.
  • MATERIALS AND METHODS: C3(1) Sv-40 large T antigen transgenic mice (n = 23) were studied with institutional animal care and use committee approval.
  • These mice were sacrificed 2 minutes after injection, and frozen slices containing ducts distended with murine ductal carcinoma in situ (DCIS) were prepared for XFM.
  • One mouse received saline and served as the control animal.
  • Hematoxylin-eosin-stained slices of mammary tissues were obtained after DCE MR imaging and XFM.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • [Cites] Biometals. 2009 Feb;22(1):197-205 [19130257.001]
  • [Cites] Scanning Microsc. 1992 Dec;6(4):1137-43; discussion 1143-5 [1295083.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11236-40 [7972041.001]
  • [Cites] Radiology. 1995 Sep;196(3):593-610 [7644617.001]
  • [Cites] J Comput Assist Tomogr. 1996 Jan-Feb;20(1):9-14 [8576489.001]
  • [Cites] Radiology. 1997 Feb;202(2):413-20 [9015067.001]
  • [Cites] Radiology. 1997 Apr;203(1):137-44 [9122382.001]
  • [Cites] Radiology. 1998 Jun;207(3):675-81 [9609890.001]
  • [Cites] J Magn Reson Imaging. 1998 Sep-Oct;8(5):1126-34 [9786152.001]
  • [Cites] Med Image Anal. 2005 Aug;9(4):315-29 [15950895.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):387-98 [15949236.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):708-18 [15971199.001]
  • [Cites] Magn Reson Imaging. 2005 Jul;23(6):733-8 [16198828.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):379-81 [16297079.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):382-90 [16297080.001]
  • [Cites] JBR-BTR. 2005 Sep-Oct;88(5):225-32 [16302331.001]
  • [Cites] J Magn Reson Imaging. 2006 Sep;24(3):646-56 [16878308.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4603-10 [17008702.001]
  • [Cites] J Magn Reson Imaging. 2006 Nov;24(5):1140-7 [17024660.001]
  • [Cites] Phys Med Biol. 2006 Dec 21;51(24):N451-9 [17148815.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89 [17392385.001]
  • [Cites] Lancet. 2007 Aug 11;370(9586):485-92 [17693177.001]
  • [Cites] Radiology. 2007 Dec;245(3):684-91 [18024450.001]
  • [Cites] J Am Chem Soc. 2007 Dec 26;129(51):15760-1 [18047347.001]
  • [Cites] Nanomedicine. 2008 Sep;4(3):201-7 [18567541.001]
  • [Cites] Eur Radiol. 2008 Oct;18(10):2164-73 [18545998.001]
  • [Cites] Phys Med Biol. 2008 Oct 7;53(19):5481-93 [18780960.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17943-8 [19004780.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1020-7 [10713685.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4272-7 [11358855.001]
  • [Cites] Br J Radiol. 2003 Jan;76(901):3-12 [12595319.001]
  • [CommentIn] Radiology. 2009 Nov;253(2):281-3 [19864520.001]
  • (PMID = 19864527.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / 1 R01 EB003108-04; United States / NCI NIH HHS / CA / R21 CA104774; United States / NCI NIH HHS / CA / R21 CA104774-01A2; United States / NIBIB NIH HHS / EB / R01 EB003108; United States / NIBIB NIH HHS / EB / R01 EB002100
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  • [Other-IDs] NLM/ PMC2770112
  •  go-up   go-down


2. McQuade P, Martin KE, Castle TC, Went MJ, Blower PJ, Welch MJ, Lewis JS: Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents. Nucl Med Biol; 2005 Feb;32(2):147-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Three 64Cu-labeled selenosemicarbazone complexes were synthesized and one was screened for hypoxia selectivity in vitro using EMT-6 mouse mammary carcinoma cells.
  • Rodent biodistribution and small animal PET images were obtained from BALB/c mice implanted with EMT-6 tumors.
  • [MeSH-major] Cell Hypoxia. Copper Radioisotopes / pharmacokinetics. Mammary Neoplasms, Animal / metabolism. Mammary Neoplasms, Animal / radionuclide imaging. Oxygen / metabolism. Semicarbazones / pharmacokinetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721760.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P30 CA91842; United States / NCI NIH HHS / CA / R24 CA86307
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Copper Radioisotopes; 0 / Radiopharmaceuticals; 0 / Semicarbazones; S88TT14065 / Oxygen
  •  go-up   go-down


3. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA: The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle; 2009 Jan 1;8(1):88-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.
  • Population studies have revealed that treatment with the antidiabetic drug metformin significantly associates with reduced breast cancer risk.
  • Animal studies have shown that metformin suppresses the development of mammary carcinomas in transgenic female mice carrying a HER2 oncogene, but not that of spontaneous tumors.
  • We herein demonstrate that HER2 oncoprotein itself may represent a key cellular target involved in the anti-breast cancer actions of metformin.
  • First, ectopical overexpression of HER2 oncogene significantly enhances metformin-induced breast cancer cell growth inhibition.
  • HER2-positive breast cancer cells transfected with p70S6K1 siRNA become completely refractory to metformin-induced HER2 suppression.
  • From the perspective of chemoprevention, these findings altogether suggest that metformin might exert a protective mostly confined to the HER2-positive breast cancer subtype.
  • From the perspective of intervention, the presence/absence of molecular hallmarks such as HER2 overexpression and/or p70S6K1 hyperactivation might dictate alternative responses in metformin-based treatment of early breast cancer.
  • The importance of mTOR/p70S6K1-sensed ROS status at mediating the anti-oncogenic effects of metformin might represent a previously unrecognized linkage molecularly connecting its anti-aging and anti-cancer actions.


Advertisement
4. Mitra SK, Lim ST, Chi A, Schlaepfer DD: Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. Oncogene; 2006 Jul 27;25(32):4429-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
  • Expression of focal adhesion kinase (FAK) is elevated in malignant breast cancer, yet the role of intrinsic FAK activity in promoting tumor progression remains undefined.
  • Here, we have inhibited FAK activity or expression in murine 4T1 breast carcinoma cells via dominant-negative focal adhesion kinase-related non-kinase (FRNK) or anti-FAK short hairpin RNA (shRNA) expression, respectively.
  • Control 4T1 cells implanted into mammary fat pads of BALB/c mice exhibited spontaneous metastasis to the lungs, to the peritoneal cavity, and resulted in 90% lethality within 21 days.
  • Whereas FAK shRNA-expressing 4T1 cells formed tumors in mice with low levels of apoptosis, when mammary-injected, these cells did not exhibit lung metastasis after 21 days and caused only 40% lethality up to 60 days.
  • Transient re-expression of wild-type but not kinase-dead FAK in 4T1 FAK shRNA cells promoted uPA production and mammary to lung metastasis within 7 days.
  • These studies provide the first direct proof that FAK catalytic activity can facilitate metastatic breast cancer progression by regulating uPA expression.
  • [MeSH-minor] Animals. Cell Line, Tumor. Disease Models, Animal. Female. Humans. Mice. Mice, Inbred BALB C

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16547501.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102310; United States / NCI NIH HHS / CA / CA75240; United States / NCI NIH HHS / CA / CA87038
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


5. Jacobs TM, Hoppe BR, Poehlmann CE, Ferracone JD, Sorenmo KU: Mammary adenocarcinomas in three male cats exposed to medroxyprogesterone acetate (1990-2006). J Feline Med Surg; 2010 Feb;12(2):169-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary adenocarcinomas in three male cats exposed to medroxyprogesterone acetate (1990-2006).
  • All three cats subsequently developed multiple recurrent mammary adenocarcinomas and underwent numerous surgical resections.
  • This report describes the clinical, histopathological and immunohistochemical findings in these three cats and highlights the potential for mammary carcinomas to develop in male cats years after receiving MPA injections.
  • Extended survival times and a long delay between the administration of the progestin injections and the onset of mammary neoplasia are noted.
  • Estrogen and progesterone receptor staining was performed on some of the tumors and the complex role of hormones in the pathogenesis and the prognosis of feline mammary carcinoma is discussed.
  • Clinicians using MPA should institute life-long surveillance of their feline patients for mammary tumors.
  • [MeSH-major] Adenocarcinoma / veterinary. Cat Diseases / chemically induced. Mammary Neoplasms, Animal / chemically induced. Medroxyprogesterone Acetate / adverse effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 ESFM and AAFP. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19818661.001).
  • [ISSN] 1532-2750
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


6. Alessio HM, Schweitzer NB, Snedden AM, Callahan P, Hagerman AE: Revisiting influences on tumor development focusing on laboratory housing. J Am Assoc Lab Anim Sci; 2009 May;48(3):258-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 64 wk, tumors in SED animals included thyroid carcinoma, malignancy, mammary fibroadenoma, cystadenoma, and granuloma, whereas benign mammary gland cysts were most common in EX.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Endocrinol Metab. 2002 Aug;13(6):245-50 [12128285.001]
  • [Cites] Epidemiol Rev. 2001;23(1):132-7 [11588837.001]
  • [Cites] Med Sci Sports Exerc. 2003 Nov;35(11):1828-33 [14600546.001]
  • [Cites] Med Sci Sports Exerc. 2003 Nov;35(11):1834-40 [14600547.001]
  • [Cites] Cancer Res. 1966 Mar;26(3):400-11 [5948819.001]
  • [Cites] Cancer Res. 1973 Nov;33(11):2768-73 [4748432.001]
  • [Cites] Br J Cancer. 1981 May;43(5):689-95 [7248153.001]
  • [Cites] Neuroendocrinology. 1985 Nov;41(5):437-44 [4058676.001]
  • [Cites] Br J Cancer. 1985 Dec;52(6):885-91 [4074640.001]
  • [Cites] Physiol Behav. 1997 Jul;62(1):105-11 [9226349.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):512-23 [10088621.001]
  • [Cites] Physiol Behav. 2005 Jan 31;84(1):65-72 [15642608.001]
  • [Cites] Med Sci Sports Exerc. 2006 Mar;38(3):405-6 [16540824.001]
  • [Cites] Mol Cell Biochem. 2007 Jan;294(1-2):19-24 [17136443.001]
  • [Cites] Med Sci Sports Exerc. 2000 Oct;32(10):1704-8 [11039641.001]
  • [Cites] Med Sci Sports Exerc. 2000 Nov;32(11):1908-12 [11079521.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):689-96 [12574200.001]
  • (PMID = 19476713.001).
  • [ISSN] 1559-6109
  • [Journal-full-title] Journal of the American Association for Laboratory Animal Science : JAALAS
  • [ISO-abbreviation] J. Am. Assoc. Lab. Anim. Sci.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R15 AG020526; United States / NIA NIH HHS / AG / R15 AG 20526-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-62-4 / Prolactin
  • [Other-IDs] NLM/ PMC2696827
  •  go-up   go-down


7. Smith AP, Henze M, Lee JA, Osborn KG, Keck JM, Tedesco D, Bortner DM, Rosenberg MP, Reed SI: Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland. Oncogene; 2006 Nov 23;25(55):7245-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland.
  • Here we show that deregulated expression of a hyperstable allele of cyclin E in mice heterozygous for p53 synergistically increases mammary tumorigenesis more than that in mice carrying either of these markers individually.
  • An indirect assay indicates that loss of p53 function is an early event occurring in the mammary epithelia of midlactation mammary glands in which cyclin E is deregulated long before evidence of malignancy.
  • Cyclin E deregulation and p53 loss are characteristics often observed in human breast carcinoma.
  • [MeSH-major] Cyclin E / physiology. Genes, p53. Loss of Heterozygosity. Mammary Glands, Animal / pathology. Mammary Neoplasms, Animal / genetics

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751806.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA78343
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin E
  •  go-up   go-down


8. Garamvölgyi R, Petrási Z, Hevesi A, Jakab C, Vajda Z, Bogner P, Repa I: Magnetic resonance imaging technique for the examination of canine mammary tumours. Acta Vet Hung; 2006 Jun;54(2):143-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging technique for the examination of canine mammary tumours.
  • The aim of this study was to adapt the human magnetic resonance imaging (MRI) sequences for use in the routine examination of canine mammary glands.
  • It was found that T1- and T2-weighted spin echo, short T1 inversion recovery sequences and a gradient echo (GE) dynamic T1-weighted measurement made in the coronal and transversal planes were the most informative MR diagnostic methods for imaging canine mammary tumours.
  • The static MR technique is the most detailed imaging modality for differentiating the tissue types in the substance of the mammary gland.
  • The MRI findings were in close relationship with the histological result (five malignant mixed tumours and five cases of invasive ductal carcinoma).
  • [MeSH-major] Carcinoma, Ductal, Breast / veterinary. Dog Diseases / pathology. Magnetic Resonance Imaging / veterinary. Mammary Neoplasms, Animal / pathology. Mixed Tumor, Malignant / veterinary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16841753.001).
  • [ISSN] 0236-6290
  • [Journal-full-title] Acta veterinaria Hungarica
  • [ISO-abbreviation] Acta Vet. Hung.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


9. Planellas M, Bassols A, Siracusa C, Saco Y, Giménez M, Pato R, Pastor J: Evaluation of serum haptoglobin and C-reactive protein in dogs with mammary tumors. Vet Clin Pathol; 2009 Sep;38(3):348-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of serum haptoglobin and C-reactive protein in dogs with mammary tumors.
  • Although mammary neoplasms are the most common type of cancer in dogs, acute phase proteins have not been extensively evaluated in dogs with mammary tumors.
  • OBJECTIVES: The aim of this study was to evaluate serum haptoglobin (Hp) and C-reactive protein (CRP) concentrations in the dogs with mammary tumors and assess their potential association with malignancy.
  • METHODS: A retrospective study of dogs with mammary tumors was performed.
  • Serum concentrations of CRP and Hp were determined in healthy control dogs (n=20) and dogs with mammary tumors before surgery (n=41).
  • Mammary tumors were grouped as carcinomas (n=24), fibrosarcoma (n=1), malignant mixed tumors (n=7), benign mixed tumors (n=6), and adenomas (n=3).
  • RESULTS: Hp concentration was significantly (P<.043) higher in dogs with mammary tumors (median 2.03 g/L, range 0.09-2.94 g/L) compared with controls (1.38 g/L, range 0.08-3.00 g/L), but the range of values overlapped considerably.
  • CRP concentration was higher in dogs with carcinomas (4.70 mg/L, range 0.63-128.96 mg/L) vs controls (2.11 mg/L, range 0.25-6.57 mg/L) (P=.0008) and in dogs with ulcerated skin (14.8 mg/L, range 5.7-128.9 mg/L, n=3) compared with those without ulceration (2.4 mg/L, range 0.11-30.3 mg/L, n=38) (P=.048).
  • CONCLUSIONS: Serum Hp and CRP do not appear to have value in diagnosing or predicting malignancy of mammary tumors in dogs.
  • Higher CRP concentrations in dogs with mammary carcinoma suggest a role for inflammation in this tumor type.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19392756.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Haptoglobins; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


10. Hui AY, Meens JA, Schick C, Organ SL, Qiao H, Tremblay EA, Schaeffer E, Uniyal S, Chan BM, Elliott BE: Src and FAK mediate cell-matrix adhesion-dependent activation of Met during transformation of breast epithelial cells. J Cell Biochem; 2009 Aug 15;107(6):1168-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This process has been linked to transformation and tumorigenesis in a variety of cancer types.
  • In the present report, we describe a key role of integrin signaling via the Src/FAK axis in the activation of Met in breast epithelial and carcinoma cells.
  • Expression of an activated Src mutant in non-neoplastic breast epithelial cells or in carcinoma cells was found to increase phosphorylation of Met at regulatory tyrosines in the auto-activation loop domain, correlating with increased cell spreading and filopodia extensions.
  • Conversely, genetic or pharmacological inhibition of Src abrogates constitutive Met phosphorylation in carcinoma cells or epithelial cells expressing activated Src, and inhibits filopodia formation.
  • [MeSH-major] Cell Transformation, Neoplastic. Focal Adhesion Protein-Tyrosine Kinases / metabolism. Mammary Neoplasms, Animal / pathology. Proto-Oncogene Proteins c-met / metabolism. src-Family Kinases / metabolism


11. Panarese S, Brunetti B, Sarli G: Evaluation of telomerase in canine mammary tissues by immunohistochemical analysis and a polymerase chain reaction-based enzyme-linked immunosorbent assay. J Vet Diagn Invest; 2006 Jul;18(4):362-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of telomerase in canine mammary tissues by immunohistochemical analysis and a polymerase chain reaction-based enzyme-linked immunosorbent assay.
  • The focus of the study reported here was to detect telomerase in 37 canine mammary samples, by comparing two methods: immunohistochemical (IHC) analysis for detecting the catalytic subunit of the enzyme, telomerase reverse transcriptase (TERT), and the telomeric repeat amplification protocol-enzyme-linked immunosorbent assay (TRAP-ELISA), a polymerase chain reaction (PCR)-based technique that uses a colorimetric detection method.
  • The detection of telomerase in normal mammary gland and fibrocystic mastopathy using both methods does not support the idea that telomerase may be used as a specific marker of mammary neoplasia in dogs.
  • [MeSH-major] Dog Diseases / enzymology. Enzyme-Linked Immunosorbent Assay / veterinary. Immunohistochemistry / veterinary. Mammary Glands, Animal / enzymology. Polymerase Chain Reaction / veterinary. Telomerase / metabolism
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / veterinary. Animals. Biomarkers. Carcinoma / diagnosis. Carcinoma / veterinary. DNA-Binding Proteins / metabolism. Dogs. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Mammary Neoplasms, Animal / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921875.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


12. Matsuda K, Kobayashi S, Yamashita M, Hirayama K, Kadosawa T, Taniyama H: Tubulopapillary carcinoma with spindle cell metaplasia of the mammary gland in a cat. J Vet Med Sci; 2008 May;70(5):479-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulopapillary carcinoma with spindle cell metaplasia of the mammary gland in a cat.
  • Sarcomatous proliferation of spindle cells was present in the mammary gland and many metastatic sites in a 10-year-old female domestic cat with tubulopapillary carcinoma in the mammary gland.
  • Transition from neoplastic tubular structures to spindle cells in the primary site and fascicular proliferation of the spindle cells with or without coexistance of tubulopapillary carcinoma in the primary and metastatic sites were observed.
  • From these results, this case was diagnosed as tubulopapillary carcinoma with spindle cell metaplasia and it was clarified that neoplastic luminal epithelial cells can transform to sarcomatous appearence.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525170.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


13. Kmieciak M, Knutson KL, Dumur CI, Manjili MH: HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol; 2007 Mar;37(3):675-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.
  • To address this question, we used rat neu-overexpressing mouse mammary carcinoma (MMC) and its relapsed neu antigen-negative variant (ANV).

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Nov 15;165(10):5502-8 [11067903.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):509-19 [11395427.001]
  • [Cites] Oncogene. 2001 Sep 20;20(42):6009-17 [11593408.001]
  • [Cites] Immunol Res. 2001;24(2):201-10 [11594457.001]
  • [Cites] J Mol Biol. 2002 Mar 22;317(2):225-35 [11902839.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3971-9 [12124329.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):991-8 [12407406.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2002 Jun;38(6):326-33 [12513120.001]
  • [Cites] Biochem J. 2003 Feb 15;370(Pt 1):323-9 [12418962.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Cytometry. 2001 Feb 1;43(2):134-42 [11169578.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1107-11 [11323675.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4054-61 [14530326.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1146-51 [14871850.001]
  • [Cites] Annu Rev Immunol. 2004;22:329-60 [15032581.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):7037-41 [2119884.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82 [1359541.001]
  • [Cites] Eur J Immunol. 1996 Aug;26(8):1844-50 [8765030.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1633-41 [8833913.001]
  • [Cites] Scand J Immunol. 1997 May;45(5):463-70 [9160088.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] J Exp Med. 1999 Jul 19;190(2):205-15 [10432284.001]
  • [Cites] Science. 2004 Dec 24;306(5705):2261-4 [15564314.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4376-88 [15899830.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):6863-71 [15905528.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6169-76 [16237114.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7470-9 [16243821.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8304-11 [16322289.001]
  • [Cites] J Immunol. 2006 Jan 15;176(2):905-13 [16393975.001]
  • [Cites] J Immunol. 2006 Apr 15;176(8):4511; author reply 4511-2 [16585536.001]
  • [Cites] Breast Cancer Res Treat. 2006 Apr;96(3):233-41 [16211331.001]
  • [Cites] J Immunol. 2006 Aug 1;177(3):1526-33 [16849459.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7536-45 [16157940.001]
  • (PMID = 17304628.001).
  • [ISSN] 0014-2980
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016059; United States / NCI NIH HHS / CA / R01 CA104757; United States / NCI NIH HHS / CA / P30CA16059
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ NIHMS498531; NLM/ PMC3732067
  •  go-up   go-down


14. Lee CG, Kwon HK, Ryu JH, Kang SJ, Im CR, Ii Kim J, Im SH: Abalone visceral extract inhibit tumor growth and metastasis by modulating Cox-2 levels and CD8+ T cell activity. BMC Complement Altern Med; 2010;10:60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In the present study, we used breast cancer model using BALB/c mouse-derived 4T1 mammary carcinoma and investigated the effect of abalone visceral extract on tumor development.
  • [MeSH-major] Adenocarcinoma / secondary. Biological Products / pharmacology. CD8-Positive T-Lymphocytes / metabolism. Cyclooxygenase 2 / metabolism. Lung Neoplasms / secondary. Mammary Neoplasms, Experimental / metabolism. Snails
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Disease Models, Animal. Female. Lung / metabolism. Lung / pathology. Mice. Mice, Inbred BALB C. RNA, Messenger / metabolism. Spleen / drug effects. Spleen / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Aug;83(3):324-8 [10917546.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1486-93 [9537252.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):5042-51 [11673513.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):625-31 [11830509.001]
  • [Cites] Clin Exp Metastasis. 1999 Mar;17(2):163-70 [10411109.001]
  • [Cites] Nat Rev Immunol. 2004 Nov;4(11):900-11 [15516969.001]
  • [Cites] J Clin Oncol. 2005 Mar 10;23(8):1782-90 [15755986.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):263-74 [15776005.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):397-405 [15864281.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]
  • [Cites] Br J Nutr. 2006 Aug;96 Suppl 1:S42-5 [16923250.001]
  • [Cites] BMC Cancer. 2006;6:181 [16831226.001]
  • [Cites] Exp Mol Pathol. 2007 Feb;82(1):12-24 [16919266.001]
  • [Cites] Nat Protoc. 2006;1(2):672-82 [17406295.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):765-70 [17429393.001]
  • [Cites] Oncogene. 2007 May 31;26(26):3789-96 [17213821.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Antioxid Redox Signal. 2008 Mar;10(3):475-510 [18154485.001]
  • [Cites] BMC Cancer. 2008;8:83 [18373849.001]
  • [Cites] Carcinogenesis. 2008 Nov;29(11):2227-35 [18725385.001]
  • [Cites] Curr Opin Oncol. 2009 Jan;21(1):53-9 [19125019.001]
  • [Cites] Carcinogenesis. 2009 Mar;30(3):377-86 [19136477.001]
  • [Cites] Cancer Lett. 2009 Jun 18;278(2):174-82 [19203831.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5996-6004 [19567680.001]
  • [Cites] Pharmacol Rep. 2010 Mar-Apr;62(2):233-44 [20508278.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):632-5 [11830510.001]
  • [Cites] J Clin Pathol. 2002 Jun;55(6):429-34 [12037025.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):231-7 [12107848.001]
  • [Cites] Nat Rev Immunol. 2002 Oct;2(10):735-47 [12360212.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5727-35 [12384531.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Lancet Oncol. 2003 Oct;4(10):605-15 [14554238.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jul;129(7):375-82 [12884024.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):11-22 [14708024.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2865-73 [15087405.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):100-2 [3581023.001]
  • [Cites] Cancer Immunol Immunother. 1987;24(3):207-12 [3594483.001]
  • [Cites] Int J Cancer. 1995 Nov 3;63(3):366-71 [7591233.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2197-205 [8708708.001]
  • [Cites] Clin Exp Immunol. 1997 Sep;109(3):501-9 [9328129.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • (PMID = 20961430.001).
  • [ISSN] 1472-6882
  • [Journal-full-title] BMC complementary and alternative medicine
  • [ISO-abbreviation] BMC Complement Altern Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biological Products; 0 / RNA, Messenger; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2972231
  •  go-up   go-down


15. de M Souza CH, Toledo-Piza E, Amorin R, Barboza A, Tobias KM: Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can Vet J; 2009 May;50(5):506-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment.
  • Canine inflammatory mammary carcinoma (IMC) is a rare, locally aggressive, highly metastatic tumor that is poorly responsive to treatment.
  • In conclusion, piroxicam should be considered as a single agent for the treatment of dogs with inflammatory mammary carcinoma.
  • [MeSH-major] Carcinoma / veterinary. Cyclooxygenase 2 / metabolism. Cyclooxygenase Inhibitors / therapeutic use. Dog Diseases / drug therapy. Mammary Neoplasms, Animal / drug therapy. Piroxicam / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vet Intern Med. 1994 Jul-Aug;8(4):273-8 [7983623.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):1014-24 [1588366.001]
  • [Cites] Vet Pathol. 2005 Nov;42(6):776-80 [16301573.001]
  • [Cites] Surg Oncol. 2005 Nov;14(3):133-43 [16154355.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4269-75 [16309227.001]
  • [Cites] J Am Vet Med Assoc. 2005 Nov 15;227(10):1625-9 [16313041.001]
  • [Cites] J Small Anim Pract. 2006 Jan;47(1):14-20 [16417605.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jul;98(1):115-20 [16538539.001]
  • [Cites] Vet Pathol. 2006 Sep;43(5):656-66 [16966442.001]
  • [Cites] Oncologist. 2006;11 Suppl 1:20-6 [16971736.001]
  • [Cites] J Vet Intern Med. 2006 Sep-Oct;20(5):1184-90 [17063714.001]
  • [Cites] J Comp Pathol. 2007 Feb-Apr;136(2-3):177-85 [17416236.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1960-8 [10874065.001]
  • [Cites] Breast Cancer Res. 2000;2(6):423-9 [11250736.001]
  • [Cites] J Am Vet Med Assoc. 2001 Jun 1;218(11):1783-6 [11394830.001]
  • [Cites] J Am Vet Med Assoc. 2001 Oct 15;219(8):1110-4 [11700710.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):252-66 [11854387.001]
  • [Cites] Vet Pathol. 2003 Mar;40(2):207-12 [12637762.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1200-8 [12654428.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(2):141-8 [12725414.001]
  • [Cites] Breast Cancer Res. 2003;5(6):284-8 [14580242.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2004 May;70(5):479-83 [15062852.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(3):214-8 [1733554.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Mar;72(3):181-6 [15664302.001]
  • (PMID = 19436636.001).
  • [ISSN] 0008-5286
  • [Journal-full-title] The Canadian veterinary journal = La revue vétérinaire canadienne
  • [ISO-abbreviation] Can. Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 13T4O6VMAM / Piroxicam; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2671873
  •  go-up   go-down


16. Dave B, Wynne R, Su Y, Korourian S, Chang JC, Simmen RC: Enhanced mammary progesterone receptor-A isoform activity in the promotion of mammary tumor progression by dietary soy in rats. Nutr Cancer; 2010;62(6):774-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced mammary progesterone receptor-A isoform activity in the promotion of mammary tumor progression by dietary soy in rats.
  • Dietary contribution to breast cancer risk, recurrence, and progression remains incompletely understood.
  • Increased consumption of soy and soy isoflavones is associated with reduced mammary cancer susceptibility in women and in rodent models of carcinogenesis.
  • In rats treated with N-methyl-N-nitrosourea, dietary intake of soy protein isolate (SPI) reduced mammary tumor occurrence but increased incidence of more invasive tumors in tumored rats, relative to the control diet casein.
  • Here we evaluated whether mammary tumor progression in tumor-bearing rats lifetime exposed to SPI is associated with deregulated progesterone receptor (PR) isoform expression.
  • In histologically normal mammary glands of rats with invasive ductal carcinoma lesions, PR-A protein levels were higher for SPI- than casein-fed rats, whereas PR-B was undetectable for both groups.
  • Increased mammary PR-A expression was associated with higher transforming growth factor-beta1, stanniocalcin-1, and CD44 transcript levels; lower E-cadherin and estrogen receptor-alpha expression; and reduced apoptotic status in ductal epithelium.
  • [MeSH-major] Genistein / administration & dosage. Isoflavones / administration & dosage. Mammary Neoplasms, Experimental / etiology. Receptors, Progesterone / physiology
  • [MeSH-minor] Animals. Antigens, CD44 / genetics. Carcinoma, Ductal, Breast / etiology. Carcinoma, Intraductal, Noninfiltrating / etiology. Cell Line, Tumor. Disease Progression. Female. Humans. Mammary Glands, Animal / chemistry. Rats. Transforming Growth Factor beta1 / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661826.001).
  • [ISSN] 1532-7914
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Isoflavones; 0 / Receptors, Progesterone; 0 / Transforming Growth Factor beta1; 0 / progesterone receptor A; 6287WC5J2L / daidzein; DH2M523P0H / Genistein
  •  go-up   go-down


17. Belletti B, Vaidya JS, D'Andrea S, Entschladen F, Roncadin M, Lovat F, Berton S, Perin T, Candiani E, Reccanello S, Veronesi A, Canzonieri V, Trovò MG, Zaenker KS, Colombatti A, Baldassarre G, Massarut S: Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res; 2008 Mar 01;14(5):1325-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding.
  • PURPOSE: After apparently successful excision of breast cancer, risk of local recurrence remains high mainly in the area surrounding the original tumor, indicating that wound healing processes may be implicated.
  • EXPERIMENTAL DESIGN: We studied how normal and mammary carcinoma cell growth and motility are affected by surgical wound fluids (WF), collected over 24 h following breast-conserving surgery in 45 patients, 20 of whom had received additional TARGeted Intraoperative radioTherapy (TARGIT), immediately after the surgical excision.
  • The proteomic profile of the WF and their effects on the activation of intracellular signal transduction pathways of breast cancer cells were also analyzed.
  • RESULTS: WF stimulated proliferation, migration, and invasion of breast cancer cell lines.
  • [MeSH-minor] Animals. Breast / cytology. Breast / radiation effects. Cell Movement. Cells, Cultured. Disease Progression. Endothelium, Vascular / cytology. Endothelium, Vascular / radiation effects. Female. Follow-Up Studies. Humans. Intraoperative Care. Mammary Glands, Animal / cytology. Mammary Glands, Animal / radiation effects. Mastectomy, Segmental. Mice. Middle Aged. NIH 3T3 Cells. Neoplasm Invasiveness. Neoplasm Recurrence, Local / prevention & control. Pilot Projects. Proteomics. Radiotherapy Dosage. Umbilical Veins / cytology. Umbilical Veins / radiation effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316551.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / 07/60/49; United Kingdom / Department of Health / / HTA/07/60/49
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Chang SC, Liao JW, Wong ML, Lai YS, Liu CI: Mammary carcinoma with sebaceous differentiation in a dog. Vet Pathol; 2007 Jul;44(4):525-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary carcinoma with sebaceous differentiation in a dog.
  • This report describes an invasive mammary carcinoma with a rare distinctive feature characterized by sebaceous differentiation of tumor cells.
  • The patient had two masses in the left fifth mammary gland.
  • Microscopically, the tumors were composed of two distinctive neoplastic components, intraductal papillary adenocarcinoma and sebaceous carcinoma.
  • The cells with abundant foamy cytoplasm that resembled sebaceous cells were also found within the intraductal papillary-like nests of mammary carcinoma, providing evidence of sebaceous metaplasia.
  • Sebaceous differentiation in a mammary gland tumor is possible, because skin appendages and ductal apparatus of the mammary gland share a common anlagen.
  • [MeSH-major] Mammary Neoplasms, Animal / pathology. Sebaceous Glands / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606516.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kondo H, Onuma M, Shibuya H, Sato T: Morphological and immunohistochemical studies of spontaneous mammary tumours in Siberian hamsters (Phodopus sungorus). J Comp Pathol; 2009 Feb-Apr;140(2-3):127-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological and immunohistochemical studies of spontaneous mammary tumours in Siberian hamsters (Phodopus sungorus).
  • Mammary tumours from 12 domestic Siberian hamsters (11 females, 1 male) were examined.
  • Histopathology revealed three subtypes: simple adenoma, tubulopapillary carcinoma, and complex carcinoma.
  • In five cases of malignant mammary tumour, focal infiltration into the surrounding fibrous connective tissue was present; however, no invasion of either lymphatics or blood vessels was observed.
  • [MeSH-major] Mammary Neoplasms, Animal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110261.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


20. Toniti W, Buranasinsup S, Kongcharoen A, Charoonrut P, Puchadapirom P, Kasorndorkbua C: Immunohistochemical determination of estrogen and progesterone receptors in canine mammary tumors. Asian Pac J Cancer Prev; 2009;10(5):907-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical determination of estrogen and progesterone receptors in canine mammary tumors.
  • Mammary gland tumors are by far the most commonly found tumors in domestic dogs.
  • In the present study, we combined histopathology with immunohistochemical staining of estrogen receptors (ER) and progesterone receptors (PR) in canine mammary gland tumors.
  • Fifty dogs with primary mammary tumors underwent surgery at the Veterinary Teaching Hospital of Mahidol University during 2005 to 2007.
  • Twenty-one were diagnosed with benign tumors classified as adenomas and benign mixed mammary gland tumors.
  • Of the malignant tumors, eighty-six percent were adenocarcinomas and 14% were malignant mixed mammary gland tumors.
  • In summary, more than half of of our benign and malignant canine mammary tumors were negatively stained for ER and PR.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Carcinoma, Ductal, Breast / metabolism. Mammary Neoplasms, Experimental / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism
  • [MeSH-minor] Animals. Dogs. Female. Immunoenzyme Techniques. Mammary Glands, Animal / metabolism. Mammary Glands, Animal / pathology. Prospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104988.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


21. Bar-Sinai A, Bassa N, Fischette M, Gottesman MM, Love DC, Hanover JA, Hochman J: Mouse mammary tumor virus Env-derived peptide associates with nucleolar targets in lymphoma, mammary carcinoma, and human breast cancer. Cancer Res; 2005 Aug 15;65(16):7223-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse mammary tumor virus Env-derived peptide associates with nucleolar targets in lymphoma, mammary carcinoma, and human breast cancer.
  • We have previously shown that the leader peptide (p14) of the Env-precursor of mouse mammary tumor virus is translocated into the nucleoli of murine T cell lymphomas that harbor this virus.
  • Using a polyclonal antibody against recombinant p14, we show here that p14 is also localized to the nucleoli of murine mammary carcinomas and some human breast cancer samples.
  • Taken together, these findings point towards a more general involvement of p14 in lymphomagenesis and mammary carcinogenesis.
  • [MeSH-major] Breast Neoplasms / virology. Cell Nucleolus / virology. Lymphoma, T-Cell / virology. Mammary Neoplasms, Experimental / metabolism. Mammary Tumor Virus, Mouse / metabolism. Viral Envelope Proteins / metabolism


22. Gear RB, Yan M, Schneider J, Succop P, Heffelfinger SC, Clegg DJ: Charles River Sprague Dawley rats lack early age-dependent susceptibility to DMBA-induced mammary carcinogenesis. Int J Biol Sci; 2007 Oct 04;3(7):408-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Charles River Sprague Dawley rats lack early age-dependent susceptibility to DMBA-induced mammary carcinogenesis.
  • Developmental stages of mammary glands influence their susceptibility to initiating events related to carcinogenesis.
  • The "window of susceptibility" to mammary carcinogenesis is classically defined as the time in early puberty when the mammary gland morphology is most sensitive to initiation events.
  • Administration of the polyaromatic hydrocarbon, 7,12-dimethylbenz(a)anthracene (DMBA), in a single oral dose yields maximal mammary tumor formation when administered in this "window".
  • We examined the DMBA treated mammary glands, precursor lesions, and morphology of the uninvolved mammary epithelium for the first 100 days of life for Charles River Sprague Dawley CD(R) IGS.
  • Our goal was to determine the DMBA dose at which 50% of the rats (IC50) developed carcinoma in situ (CIS) within three months of dosing.
  • Additionally, we report that vehicle-treated animals developed mammary CIS without any known initiator, and 100 day virgin animals demonstrated lactational changes, independent of DMBA exposure or dose.
  • Lastly, we demonstrate this strain of virgin female rats has elevated pituitary prolactin immunoreactivity independent of the level of mammary differentiation.
  • We conclude this strain of Charles River Sprague Dawley rats has prolactin-induced pituitary stimulation, and therefore, the window of susceptibility for mammary tumorigenesis is absent.

  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1979 Sep;96(3):721-36 [112872.001]
  • [Cites] Cancer Res. 1980 Aug;40(8 Pt 1):2677-87 [7388818.001]
  • [Cites] J Natl Cancer Inst. 1978 Dec;61(6):1439-49 [102856.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):989-98 [15170218.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):409-20 [14973385.001]
  • [Cites] Lab Invest. 2003 Jul;83(7):1001-11 [12861040.001]
  • [Cites] Evol Dev. 2003 Jan-Feb;5(1):67-75 [12492412.001]
  • [Cites] Toxicol Lett. 2002 Jul 21;133(2-3):181-91 [12119126.001]
  • [Cites] Carcinogenesis. 2001 Jul;22(7):1027-33 [11408345.001]
  • [Cites] Toxicol Sci. 2001 Jul;62(1):46-53 [11399792.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Apr;5(2):187-200 [11149572.001]
  • [Cites] Lab Invest. 2000 Apr;80(4):485-92 [10780665.001]
  • [Cites] Lab Invest. 2000 Feb;80(2):221-31 [10701691.001]
  • [Cites] Endocrinology. 2000 Feb;141(2):476-86 [10650926.001]
  • [Cites] J Nutr. 1999 Oct;129(10):1820-6 [10498753.001]
  • [Cites] Fundam Appl Toxicol. 1996 Oct;33(2):196-211 [8921338.001]
  • [Cites] Environ Health Perspect. 1996 Sep;104(9):938-67 [8899375.001]
  • [Cites] Lab Anim Sci. 1996 Feb;46(1):67-70 [8699823.001]
  • [Cites] Carcinogenesis. 1994 Jul;15(7):1341-6 [8033309.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2402-7 [1568209.001]
  • [Cites] Lab Invest. 1990 Mar;62(3):244-78 [2107367.001]
  • [Cites] Life Sci. 1986 Sep 8;39(10):937-44 [3489150.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):3958-63 [3089584.001]
  • [Cites] Breast Cancer Res Treat. 1982;2(1):5-73 [6216933.001]
  • [Cites] Int J Cancer. 1983 Mar 15;31(3):321-7 [6402455.001]
  • [Cites] J Natl Cancer Inst. 1986 Feb;76(2):339-45 [3080638.001]
  • (PMID = 17940635.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / U01 ES012770; United States / NCI NIH HHS / CA / U01 ES/CA 012770-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Australia
  • [Chemical-registry-number] 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ PMC2017109
  • [Keywords] NOTNLM ; Charles River Sprague Dawley rats / DMBA / mammary carcinogenesis
  •  go-up   go-down


23. Rossi G, Errico G, Perez P, Rossi G, Paltrinieri S: Paraneoplastic hypoglycemia in a diabetic dog with an insulin growth factor-2-producing mammary carcinoma. Vet Clin Pathol; 2010 Dec;39(4):480-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic hypoglycemia in a diabetic dog with an insulin growth factor-2-producing mammary carcinoma.
  • The dog also had a solid ductal mammary carcinoma with very rapid growth, which was temporally related to onset of hypoglycemia.
  • During subsequent months, serum glucose concentrations remained at life-threatening levels (1.64-2.12 mmol/L, reference interval 4.44-6.66 mmol/L) simultaneously with an increase in the size of the mammary tumor, which reached a diameter of about 16 cm.
  • The glucose concentration continued to rise and reached 9.99 mmol/L 12 hours after the removal of the mammary tumor.

  • MedlinePlus Health Information. consumer health - Diabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 American Society for Veterinary Clinical Pathology.
  • (PMID = 21039714.001).
  • [ISSN] 1939-165X
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


24. Li Z, Tognon CE, Godinho FJ, Yasaitis L, Hock H, Herschkowitz JI, Lannon CL, Cho E, Kim SJ, Bronson RT, Perou CM, Sorensen PH, Orkin SH: ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell; 2007 Dec;12(6):542-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex.
  • To better understand the cellular origin of breast cancer, we developed a mouse model that recapitulates expression of the ETV6-NTRK3 (EN) fusion oncoprotein, the product of the t(12;15)(p13;q25) translocation characteristic of human secretory breast carcinoma.
  • Activation of EN expression in mammary tissues by Wap-Cre leads to fully penetrant, multifocal malignant breast cancer with short latency.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 1995 Jul;121(7):2079-90 [7635053.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):366-77 [17637753.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):963-76 [9001250.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 1;25(21):4323-30 [9336464.001]
  • [Cites] Nat Genet. 1998 Feb;18(2):184-7 [9462753.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1451-8 [9811336.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5046-8 [9823307.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1355-63 [9949179.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1603-8 [9990071.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5037-42 [10220414.001]
  • [Cites] J Pathol. 2005 Jan;205(2):248-54 [15641021.001]
  • [Cites] Oncogene. 2005 Jan 20;24(4):552-60 [15580303.001]
  • [Cites] Nat Biotechnol. 1999 Nov;17(11):1091-6 [10545915.001]
  • [Cites] Oncogene. 2000 Feb 17;19(7):906-15 [10702799.001]
  • [Cites] EMBO J. 2000 May 2;19(9):2056-68 [10790372.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Oncogene. 2001 May 17;20(22):2771-80 [11420689.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(1):61-70 [11518467.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8909-16 [11751416.001]
  • [Cites] Development. 2002 Mar;129(6):1377-86 [11880347.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):245-50 [11902580.001]
  • [Cites] Dev Biol. 2002 May 1;245(1):42-56 [11969254.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7680-9 [12400010.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):347-8 [12450787.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):367-76 [12450792.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8850-5 [12857959.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]
  • [Cites] Mol Imaging. 2003 Oct;2(4):297-302 [14717328.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jul;86(2):139-52 [15319566.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6980-5 [15286714.001]
  • [Cites] Dev Biol. 1995 Mar;168(1):47-61 [7883078.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1434-44 [15608675.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):17-24 [15886883.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):25-36 [15886884.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Sep;6(9):715-25 [16231422.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Nature. 2006 Jan 5;439(7072):84-8 [16397499.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3396-400 [16585160.001]
  • [Cites] Hum Pathol. 2006 Jun;37(6):668-74 [16733206.001]
  • [Cites] Dev Biol. 2006 Jul 15;295(2):589-603 [16678816.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):818-22 [16862118.001]
  • [Cites] Nat Cell Biol. 2007 Feb;9(2):201-9 [17187062.001]
  • [Cites] BMC Cancer. 2007;7:17 [17254320.001]
  • [Cites] J Cell Physiol. 2007 Sep;212(3):729-36 [17443685.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):545-6 [17671492.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):595-9 [17671502.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):160-70 [17692807.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:675-99 [17645413.001]
  • [Cites] Dev Dyn. 1996 Jun;206(2):159-68 [8725283.001]
  • (PMID = 18068631.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE9343/ GSE9353/ GSE9354/ GSE9355
  • [Grant] United States / NCI NIH HHS / CA / U01 CA105423; United States / NCI NIH HHS / CA / R01 CA101227; United States / NCI NIH HHS / CA / N01CN43308; United States / NCI NIH HHS / CN / N01-CN43308; United States / NCI NIH HHS / CA / U01 CA105423-03; United States / NCI NIH HHS / CA / R01-CA-101227; United States / NCI NIH HHS / CA / U01 CA105423-04; United States / NCI NIH HHS / CA / CA105423-04; United States / NCI NIH HHS / CA / CA105423-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / ETS translocation variant 6 protein; 0 / ETV6-NTRK3 fusion protein, mouse; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / Proto-Oncogene Proteins c-jun; 0 / Repressor Proteins; 0 / Transcription Factor AP-1; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ NIHMS36102; NLM/ PMC2175032
  •  go-up   go-down


26. de Las Mulas JM, Millán Y, Dios R: A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet Pathol; 2005 Mar;42(2):200-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog.
  • The immunohistochemically determined estrogen receptor (ER) alpha (ERalpha) and progesterone receptor (PR) status, as well as recognized, well-accepted prognostic indicators and host factors were prospectively analyzed in 84 cases of primary canine mammary carcinoma for their effect on disease-free period (recurrence free, metastasis free, or combined) (DFP) after an observation period of 18 months.
  • In the group of malignant tumors (n=155), the presence of one or both receptors was more frequent in tumors smaller than 3 cm, without lymph node metastasis, with tubulopapillary rather than solid patterns of growth among simple carcinomas, of histologic grades I and II, without both intravascular growth and necrosis, and with lymphocyte cell infiltrates.
  • [MeSH-major] Dog Diseases / pathology. Estrogen Receptor alpha / physiology. Gene Expression / physiology. Mammary Neoplasms, Animal / pathology. Receptors, Progesterone / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753474.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone
  •  go-up   go-down


27. Rossini A, Rumio C, Sfondrini L, Tagliabue E, Morelli D, Miceli R, Mariani L, Palazzo M, Ménard S, Balsari A: Influence of antibiotic treatment on breast carcinoma development in proto-neu transgenic mice. Cancer Res; 2006 Jun 15;66(12):6219-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of antibiotic treatment on breast carcinoma development in proto-neu transgenic mice.
  • The effect of prolonged antibiotic treatments on tumor development was evaluated in proto-neu transgenic mice, which spontaneously develop mammary carcinomas.
  • The hazard ratio [HR; 95% confidence interval (95% CI)] of breast cancer occurrence in metronidazole/ciprofloxacin-treated mice was more than triple that for controls [3.11 (1.13-8.53); P = 0.028], whereas only a slight increase in HR (95% CI) was observed in gentamicin-treated mice [1.39 (0.56-3.47); P = 0.481].
  • Moreover, mammary glands from mice treated with either antibiotic regimen showed increased lobulization, with more numerous and more developed terminal ductal lobular units than in controls.
  • These results indicate that prolonged exposure to relevant doses of antibiotics affects the mammary glands in this particular model of HER-2/neu transgenic mice; further studies to understand the precise mechanism by which antibiotic treatments influence mammary gland differentiation are critical.
  • [MeSH-major] Anti-Infective Agents / toxicity. Genes, erbB-2. Mammary Neoplasms, Experimental / chemically induced. Mammary Neoplasms, Experimental / genetics
  • [MeSH-minor] Animals. Cell Growth Processes / drug effects. Cell Growth Processes / physiology. Ciprofloxacin / toxicity. Cocarcinogenesis. Female. Genetic Predisposition to Disease. Gentamicins / toxicity. Mammary Glands, Animal / drug effects. Metronidazole / toxicity. Mice. Mice, Transgenic. Rats

  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778196.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Gentamicins; 140QMO216E / Metronidazole; 5E8K9I0O4U / Ciprofloxacin
  •  go-up   go-down


28. McElroy MC, Bassett HF: Mammary carcinoma in a ewe. J Vet Diagn Invest; 2010 Nov;22(6):1006-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary carcinoma in a ewe.
  • Mammary tumors of all types are rare in herbivores, and there is a particular paucity of reports in sheep.
  • The present report describes a case of mammary carcinoma in a 6-year-old uniparous ewe.
  • It was classified as a low-grade carcinoma.
  • [MeSH-major] Mammary Neoplasms, Animal / pathology. Sheep Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21088195.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Montel V, Mose ES, Tarin D: Tumor-stromal interactions reciprocally modulate gene expression patterns during carcinogenesis and metastasis. Int J Cancer; 2006 Jul 15;119(2):251-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study used a unique xenogeneic breast cancer model to study the effects of tumor cells and neighboring host cells upon each other in tumor growth and metastasis.
  • It was found that the gene expression profiles of highly and poorly metastatic clones from the same human breast carcinoma changed differentially when the cells were transferred from growth in vitro to the mammary gland.
  • We describe novel sets of genes, validated by human-specific probes, which were induced in the 2 isogenic, but phenotypically different, tumor lineages by the mammary environment.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Mammary Neoplasms, Experimental / metabolism. Mammary Neoplasms, Experimental / pathology. Neoplasm Metastasis / pathology. Stromal Cells
  • [MeSH-minor] Animals. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Line, Tumor. Disease Models, Animal. Dissection / instrumentation. Enzyme-Linked Immunosorbent Assay. Female. Humans. Laser Therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Mammary Glands, Animal. Mice. Mice, Nude. Mice, SCID. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16482564.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Cardazzo B, Zappulli V, Frassineti F, Patarnello T, Castagnaro M, Bargelloni L: Full-length sequence and expression analysis of estrogen receptor alpha mRNA in feline mammary tumors. J Steroid Biochem Mol Biol; 2005 Jul;96(2):109-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full-length sequence and expression analysis of estrogen receptor alpha mRNA in feline mammary tumors.
  • Expression analysis of exon-deleted variants was also conducted on 24 samples of feline mammary carcinoma (FMC) and 15 normal mammary gland (NMG) controls, using a "splice targeted approach".
  • [MeSH-major] Estrogen Receptor alpha / genetics. Mammary Neoplasms, Animal / genetics. RNA, Messenger / genetics
  • [MeSH-minor] 5' Untranslated Regions. Alternative Splicing. Animals. Cats. DNA Primers. Female. Gene Expression Regulation. Genetic Variation. Mammary Glands, Animal / physiology. Organ Specificity. Ovary / physiology. Polymerase Chain Reaction. RNA / genetics. RNA / isolation & purification. Reference Values. Sequence Deletion

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955691.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / DNA Primers; 0 / Estrogen Receptor alpha; 0 / RNA, Messenger; 63231-63-0 / RNA
  •  go-up   go-down


31. Elazar V, Adwan H, Bäuerle T, Rohekar K, Golomb G, Berger MR: Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. Int J Cancer; 2010 Apr 1;126(7):1749-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis.
  • Poor prognosis in mammary carcinoma is associated with a certain expression profile of a defined set of genes including osteopontin and bone sialoprotein.
  • The therapeutic efficacy of the AS-NP delivery system was examined in vitro, and in a breast cancer bone metastasis animal model of MDA-MB-231 human breast cancer cells in nude rats.

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19739076.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IBSP protein, human; 0 / Integrin-Binding Sialoprotein; 0 / Oligonucleotides, Antisense; 0 / Sialoglycoproteins; 0 / polylactic acid-polyglycolic acid copolymer; 106441-73-0 / Osteopontin; 26009-03-0 / Polyglycolic Acid; 33X04XA5AT / Lactic Acid
  •  go-up   go-down


32. Rodo A, Malicka E: E-cadherin immunohistochemical expression in mammary gland neoplasms in bitches. Pol J Vet Sci; 2008;11(1):47-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E-cadherin immunohistochemical expression in mammary gland neoplasms in bitches.
  • Material for the investigation comprised mammary gland tumours, collected from dogs, the patients of veterinary clinics, during surgical procedures and archival samples.
  • All together 21 adenomas, 32 complex carcinomas, 35 simple carcinomas and 13 solid carcinomas were qualified for further investigation.
  • E-cadherin expression was higher in adenomas as compared with carcinomas but lower in solid carcinomas as compared with simple and complex carcinomas.
  • [MeSH-major] Adenoma / veterinary. Cadherins / metabolism. Carcinoma / veterinary. Dog Diseases / metabolism. Mammary Neoplasms, Animal / enzymology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540208.001).
  • [ISSN] 1505-1773
  • [Journal-full-title] Polish journal of veterinary sciences
  • [ISO-abbreviation] Pol J Vet Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


33. Borowsky A: Special considerations in mouse models of breast cancer. Breast Dis; 2007;28:29-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Special considerations in mouse models of breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Mammary Neoplasms, Experimental / genetics
  • [MeSH-minor] Adenosine Triphosphatases. Animals. Cadherins. Carcinoma, Lobular / genetics. Carcinoma, Lobular / pathology. DNA Helicases. Female. Genes, BRCA1. Genes, BRCA2. Genes, p53. Humans. Mammary Glands, Animal / anatomy & histology. Mammary Glands, Human / anatomy & histology. Mice. Mice, Knockout. Mice, Transgenic. Neoplasm Transplantation. RecQ Helicases. Receptor, ErbB-2 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057541.001).
  • [ISSN] 0888-6008
  • [Journal-full-title] Breast disease
  • [ISO-abbreviation] Breast Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / Bloom syndrome protein; EC 3.6.4.- / DNA Helicases; EC 3.6.4.12 / RecQ Helicases
  • [Number-of-references] 51
  •  go-up   go-down


34. Moraes RC, Zhang X, Harrington N, Fung JY, Wu MF, Hilsenbeck SG, Allred DC, Lewis MT: Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development; 2007 Mar;134(6):1231-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia.
  • Altered hedgehog signaling is implicated in 20-25% of all cancers, including breast cancer.
  • We demonstrated previously that heterozygous disruption of the gene encoding the patched-1 (PTCH1) hedgehog receptor, a negative regulator of smoothened (Smo) in the absence of ligand, led to mammary ductal dysplasia in virgin mice.
  • We now show that expression of activated human SMO (SmoM2) under the mouse mammary tumor virus (MMTV) promoter in transgenic mice leads to increased proliferation, altered differentiation, and ductal dysplasias distinct from those caused by Ptch1 heterozygosity.
  • SMO activation also increased the mammosphere-forming efficiency of primary mammary epithelial cells.
  • In human clinical samples, altered hedgehog signaling occurs early in breast cancer development, with PTCH1 expression reduced in approximately 50% of ductal carcinoma in situ (DCIS) and invasive breast cancers (IBC).
  • Our data suggest that altered hedgehog signaling may contribute to breast cancer development by stimulating proliferation, and by increasing the pool of division-competent cells capable of anchorage-independent growth.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Fibrocystic Breast Disease / etiology. Hedgehog Proteins / metabolism. Mammary Glands, Animal / metabolism. Receptors, G-Protein-Coupled / metabolism
  • [MeSH-minor] Animals. Apoptosis. Caspase 3 / metabolism. Cell Differentiation. Cell Proliferation. Humans. Ki-67 Antigen / analysis. Ki-67 Antigen / metabolism. Mammary Tumor Virus, Mouse / genetics. Mice. Mice, Transgenic. Promoter Regions, Genetic. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Transgenes

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287253.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA30195; United States / NCI NIH HHS / CA / P50-CA58183
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Ki-67 Antigen; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / SMO protein, human; 0 / patched receptors; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


35. Ashour M, Edrada R, Ebel R, Wray V, Wätjen W, Padmakumar K, Müller WE, Lin WH, Proksch P: Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia. J Nat Prod; 2006 Nov;69(11):1547-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The new derivative kahalalide R was found to exert comparable or even higher cytotoxicity than the potential drug candidate kahalalide F toward the MCF7 human mammary carcinoma cell line.
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Screening Assays, Antitumor. Female. Humans. Indian Ocean. Mammary Neoplasms, Animal. Molecular Structure. Nuclear Magnetic Resonance, Biomolecular

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17125219.001).
  • [ISSN] 0163-3864
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsipeptides; 0 / kahalalide R; 0 / kahalalide S; 149204-42-2 / kahalalide F
  •  go-up   go-down


36. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res; 2005 Jan 15;11(2 Pt 1):728-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.
  • PURPOSE: Ionizing radiation therapy (RT) is an important component in the management of breast cancer.
  • Although the primary tumor can be successfully treated by surgery and RT, metastatic breast cancer remains a therapeutic challenge.
  • EXPERIMENTAL DESIGN: The poorly immunogenic metastatic mouse mammary carcinoma 4T1 was used as a model.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, Differentiation / therapeutic use. Mammary Neoplasms, Experimental / immunology. Mammary Neoplasms, Experimental / therapy
  • [MeSH-minor] Animals. Antigens, CD. CTLA-4 Antigen. Cobalt Radioisotopes. Combined Modality Therapy. Disease Models, Animal. Female. Immunoglobulin Fc Fragments / chemistry. Immunoglobulin Fc Fragments / immunology. Immunoglobulin Fc Fragments / therapeutic use. Immunosuppressive Agents / chemistry. Immunosuppressive Agents / immunology. Immunosuppressive Agents / therapeutic use. Lung Neoplasms / immunology. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Mice. Mice, Inbred BALB C. Radiotherapy Dosage. Survival Rate

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701862.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA 89336
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Differentiation; 0 / CTLA-4 Antigen; 0 / Cobalt Radioisotopes; 0 / Ctla4 protein, mouse; 0 / Immunoglobulin Fc Fragments; 0 / Immunosuppressive Agents
  •  go-up   go-down


37. Zhang H, Stephens LC, Kumar R: Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res; 2006 Mar 1;12(5):1479-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
  • PURPOSE: Chromatin remodeling pathways are critical in the regulation of cancer-related genes and are currently being explored as potential targets for therapeutic intervention.
  • The metastasis tumor antigen (MTA) family of proteins, MTA1, MTA2, and MTA3, are components of chromatin remodeling pathways with potential roles in breast cancer.
  • Although all three MTA family proteins have been shown to be associated with metastatic progression of breast cancers, the expression characteristic of MTA1-3 proteins in a multistep breast cancer progression model remains unknown.
  • This led us to hypothesize that each member of the MTA family possesses a unique role and interacts with different pathways in the stepwise process of breast cancer development and progression.
  • EXPERIMENTAL DESIGN: MTA family proteins were examined by immunohistochemistry in breast cancer processes ranging from normal duct, to premalignant lesions, to invasive carcinoma, and to metastasized tumors in PyV-mT transgenic mice, which represents a reliable model for multistage tumorigenesis of human breast cancer.
  • We also determined the association of MTA proteins with the status of cell proliferation, ER, E-cadherin and cytoplasmic beta-catenin, and cancer-related coactivators, AIB1 and PELP1.
  • Altered expression of MTA1 was observed in both premalignant lesion and malignant carcinoma, but an elevated nuclear expression was observed in ER-negative carcinomas.
  • MTA3 was exclusively expressed in a subset of cells of ER-positive premalignant lesions but not in carcinomas.
  • CONCLUSIONS: The findings presented here support the notion that each member of the MTA family might potentially play a stepwise role in a cell type-specific manner during breast cancer progression to metastasis.
  • On the basis of the noted temporal expression patterns of MTA proteins with ER status, cell adhesion-essential regulators (E-cadherin and cytoplasmic beta-catenin), and coactivators, we propose that MTA protein-related chromatin remodeling pathways interact with steroid receptors, growth factor receptors, and other transcriptional signaling pathways to orchestrate the governing of events in breast cancer progression and metastasis.
  • [MeSH-major] Disease Models, Animal. Mammary Neoplasms, Experimental / metabolism. Neoplasm Proteins / physiology. Repressor Proteins / physiology. Transcription Factors / physiology
  • [MeSH-minor] Animals. Antigens, Polyomavirus Transforming / physiology. Cadherins / metabolism. Carcinoma, Ductal, Breast / etiology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / etiology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Adhesion. Cell Differentiation. Cell Proliferation. Chromatin Assembly and Disassembly. Co-Repressor Proteins. Cytoplasm / metabolism. Disease Progression. Female. Hyperplasia / etiology. Hyperplasia / metabolism. Hyperplasia / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mice. Mice, Transgenic. Neoplasm Invasiveness / pathology. Nuclear Receptor Coactivator 3. Precancerous Conditions / etiology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Receptors, Estrogen / metabolism. Signal Transduction. Trans-Activators / metabolism. beta Catenin / metabolism

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533771.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA90970; United States / NCI NIH HHS / CA / CA98823
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Cadherins; 0 / Co-Repressor Proteins; 0 / Mta1 protein, mouse; 0 / Mta3 protein, mouse; 0 / Neoplasm Proteins; 0 / PELP1 protein, human; 0 / Receptors, Estrogen; 0 / Repressor Proteins; 0 / Trans-Activators; 0 / Transcription Factors; 0 / beta Catenin; EC 2.3.1.48 / Nuclear Receptor Coactivator 3
  •  go-up   go-down


38. Qi H, Li YH, Zheng SB: [Oral gene therapy via live attenuated Salmonella leads to tumor regression and survival prolongation in mice]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Dec;26(12):1738-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Administration, Oral. Animals. Carcinoma, Lewis Lung / therapy. Flow Cytometry. Genetic Vectors / administration & dosage. Genetic Vectors / genetics. Genetic Vectors / metabolism. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Mammary Neoplasms, Animal / therapy. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Microscopy, Confocal. Vaccines, Attenuated / immunology

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17259109.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vaccines, Attenuated; 147336-22-9 / Green Fluorescent Proteins; 187348-17-0 / Interleukin-12
  •  go-up   go-down


39. Sever A, Broillet A, Schneider M, Cox K, Jones S, Weeks J, Mills P, Fish D, Jones P: Dynamic visualization of lymphatic channels and sentinel lymph nodes using intradermal microbubbles and contrast-enhanced ultrasound in a swine model and patients with breast cancer. J Ultrasound Med; 2010 Dec;29(12):1699-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic visualization of lymphatic channels and sentinel lymph nodes using intradermal microbubbles and contrast-enhanced ultrasound in a swine model and patients with breast cancer.
  • OBJECTIVE: Sentinel lymph node (SLN) identification using intradermal micro-bubbles and contrast-enhanced ultrasound (CEUS) has been recently reported in swine models and patients with breast cancer.
  • We also performed a detailed study of the passage of microbubbles through breast lymphatic channels in a small group of patients with breast cancer.
  • METHODS: Nine anesthetized healthy pigs were used for the study, and 5 female patients with primary breast cancer were recruited.
  • In all 5 patients with breast cancer, the microbubble contrast agent entered breast lymphatic channels and traveled to draining ipsilateral axillary SLNs within 3 minutes.
  • The ability to rapidly identify SLNs in the diagnostic period would enable targeted biopsy and may facilitate preoperative axillary staging in patients with early breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. Lymph Nodes / ultrasonography. Lymphatic Vessels / ultrasonography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Animals. Disease Models, Animal. Female. Humans. Image Enhancement. Injections, Intradermal. Microbubbles. Middle Aged. Phospholipids. Sulfur Hexafluoride. Swine

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21098840.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


40. Goepfert TM, Moreno-Smith M, Edwards DG, Pathak S, Medina D, Brinkley WR: Loss of chromosomal integrity drives rat mammary tumorigenesis. Int J Cancer; 2007 Mar 1;120(5):985-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of chromosomal integrity drives rat mammary tumorigenesis.
  • Breast cancer incidence varies with diet and other environmental influences, including carcinogen exposure.
  • Here, we have examined processes that are activated in the mammary glands of rats treated with 1-methyl-1-nitrosourea (MNU).
  • This synthetic carcinogen was used to study events occurring during mammary tumor initiation and development.
  • In mammary tumors, elevated numbers of centrosomes coincided with genomic instability.
  • Collectively, these data suggest that the carcinogen MNU induces changes resulting in genetic instability detectable before hyperplasia and tumors develop in the rat mammary gland.
  • [MeSH-major] Carcinoma / genetics. Carcinoma / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Chromosomal Instability. Mammary Glands, Animal / pathology. Mammary Neoplasms, Experimental / genetics. Mammary Neoplasms, Experimental / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17131329.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 41424; United States / NCI NIH HHS / CA / CA 64255
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 684-93-5 / Methylnitrosourea; EC 2.7.11.1 / Aurka protein, rat; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


41. Wang Y, Wang W, Li J, Tang J: Gray-scale contrast-enhanced ultrasonography of sentinel lymph nodes in a metastatic breast cancer model. Acad Radiol; 2009 Aug;16(8):957-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gray-scale contrast-enhanced ultrasonography of sentinel lymph nodes in a metastatic breast cancer model.
  • This study is to investigate the usefulness of SonoVue (a sonographic contrast agent) and gray-scale contrast-enhanced ultrasonography (CEUS) for detecting the SLNs in a metastatic breast cancer model.
  • [MeSH-major] Breast Neoplasms / radiography. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / secondary. Image Enhancement / methods. Lymph Nodes / ultrasonography. Phospholipids. Sulfur Hexafluoride. Ultrasonography, Mammary / methods
  • [MeSH-minor] Animals. Cell Line, Tumor. Contrast Media. Disease Models, Animal. Female. Humans. Rabbits. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427801.001).
  • [ISSN] 1878-4046
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


42. Klopfleisch R, Hvid H, Klose P, da Costa A, Gruber AD: Insulin receptor is expressed in normal canine mammary gland and benign adenomas but decreased in metastatic canine mammary carcinomas similar to human breast cancer. Vet Comp Oncol; 2010 Dec;8(4):293-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin receptor is expressed in normal canine mammary gland and benign adenomas but decreased in metastatic canine mammary carcinomas similar to human breast cancer.
  • Insulin receptor (INSR) or insulin-like growth factor (IGF) signalling is speculated to be involved in mammary tumour development.
  • Expression levels of members of the insulin receptor family (INSR, IGF1R, IGF2R, GHR) and their ligands IGF1and IGF2 were quantified in macro- and microdissected tissue samples of normal canine mammary gland, adenomas, carcinomas and their lymph node metastases to evaluate their potential impact on the carcinogenesis of canine mammary tumours.
  • Normal mammary gland and adenomas had strong INSR expression, while carcinomas and metastases had significantly decreased expression.
  • IGF1, IGF2 and GHR mRNA expressions were strongly decreased in adenomas, carcinomas and metastases.
  • However, decreased INSR expression carcinomas and their metastases render questionable its impact at late stages of carcinogenesis.
  • [MeSH-major] Adenoma / veterinary. Carcinoma / veterinary. Dog Diseases / metabolism. Mammary Glands, Animal / metabolism. Mammary Neoplasms, Animal / metabolism. Receptor, Insulin / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 21062411.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Insulin
  •  go-up   go-down


43. Targeting early stage DCIS breast cancer directly in the ducts with intraductal chemotherapy. Cancer Biol Ther; 2006 Mar;5(3):249-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting early stage DCIS breast cancer directly in the ducts with intraductal chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Intraductal, Noninfiltrating / drug therapy
  • [MeSH-minor] Animals. Clinical Trials, Phase I as Topic. Humans. Mammary Neoplasms, Animal / drug therapy. Mammary Neoplasms, Animal / prevention & control

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16812935.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] News; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


44. Lingappa M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, Sgouros G: Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res; 2010 Sep 01;70(17):6815-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.
  • Current treatment for late-stage metastatic breast cancer is largely palliative. alpha-Particles are highly potent, short-range radiation emissions capable of sterilizing individual cells with one to three traversals of the cell nucleus.
  • Efficacy in a rat/neu transgenic mouse model of metastatic mammary carcinoma was investigated.
  • We have shown that the (213)Bi radiolabeled immunoliposomes are effective in treating early-stage micrometastases, giving median survival times similar to those obtained with antibody-mediated delivery of (213)Bi in this animal model.
  • [MeSH-major] Bismuth / administration & dosage. Immunoconjugates / administration & dosage. Mammary Neoplasms, Experimental / radiotherapy. Radioimmunotherapy / methods. Radioisotopes / administration & dosage

  • Hazardous Substances Data Bank. BISMUTH, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biother Radiopharm. 2004 Dec;19(6):706-15 [15665617.001]
  • [Cites] Health Phys. 1960 Feb;2:225-38 [13818815.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11631-8 [16357174.001]
  • [Cites] Curr Pharm Des. 2006;12(36):4729-49 [17168775.001]
  • [Cites] Bioconjug Chem. 2007 Nov-Dec;18(6):2061-7 [17935286.001]
  • [Cites] Expert Opin Drug Deliv. 2008 Feb;5(2):189-204 [18248318.001]
  • [Cites] Cancer Biother Radiopharm. 2008 Feb;23(1):74-81 [18298331.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3873-80 [18483272.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6116-24 [18829490.001]
  • [Cites] Cancer Res. 2009 Dec 1;69(23):8941-8 [19920193.001]
  • [Cites] J Nucl Med. 2010 Feb;51(2):311-28 [20080889.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1935-46 [10565792.001]
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):691-743 [10581328.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3569-76 [10910070.001]
  • [Cites] Pharm Res. 2002 Mar;19(3):265-9 [11934232.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):253-60 [14960644.001]
  • [Cites] Science. 2004 Mar 19;303(5665):1818-22 [15031496.001]
  • [Cites] Expert Opin Ther Targets. 2004 Aug;8(4):335-53 [15268628.001]
  • [Cites] Bioconjug Chem. 1992 Jul-Aug;3(4):342-5 [1390990.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3765-70 [8339289.001]
  • [Cites] Biochim Biophys Acta. 1994 Feb 23;1190(1):99-107 [8110825.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3352-6 [8012948.001]
  • [Cites] Nucl Med Biol. 1995 Apr;22(3):387-90 [7627155.001]
  • [Cites] J Nucl Med. 1995 Sep;36(9):1639-44 [7658225.001]
  • [Cites] J Leukoc Biol. 1996 Sep;60(3):337-44 [8830790.001]
  • [Cites] Biochemistry. 1997 Jan 7;36(1):66-75 [8993319.001]
  • [Cites] J Nucl Med. 1997 Mar;38(3):489-93 [9074545.001]
  • [Cites] Appl Radiat Isot. 1999 May;50(5):895-904 [10214708.001]
  • [Cites] Int J Pharm. 1999 Oct 15;188(1):87-95 [10528086.001]
  • [Cites] J Biol Chem. 1959 Mar;234(3):466-8 [13641241.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6288-91 [16194090.001]
  • (PMID = 20651254.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113797; United States / NCI NIH HHS / CA / R01 CA113797-04; United States / NCI NIH HHS / CA / R01 CA187037
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoconjugates; 0 / Isothiocyanates; 0 / Liposomes; 0 / Radioisotopes; 142434-84-2 / N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid; 7A314HQM0I / Pentetic Acid; EC 2.7.10.1 / Receptor, ErbB-2; U015TT5I8H / Bismuth
  • [Other-IDs] NLM/ NIHMS248891; NLM/ PMC2977986
  •  go-up   go-down


45. Bertuzzi A, Fasano A, Gandolfi A, Sinisgalli C: Necrotic core in EMT6/Ro tumour spheroids: Is it caused by an ATP deficit? J Theor Biol; 2010 Jan 7;262(1):142-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenosine Triphosphate / deficiency. Carcinoma / pathology. Mammary Neoplasms, Animal / pathology. Spheroids, Cellular / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781558.001).
  • [ISSN] 1095-8541
  • [Journal-full-title] Journal of theoretical biology
  • [ISO-abbreviation] J. Theor. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 33X04XA5AT / Lactic Acid; 8L70Q75FXE / Adenosine Triphosphate; IY9XDZ35W2 / Glucose; S88TT14065 / Oxygen
  •  go-up   go-down


46. Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J, Borst P, Rottenberg S: Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res; 2010 Feb 15;70(4):1700-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
  • There is no tailored therapy yet for human basal-like mammary carcinomas.
  • We have evaluated this putative synthetic lethality in a genetically engineered mouse model for BRCA1-associated breast cancer, using the topoisomerase I (Top1) poison topotecan as monotherapy and in combination with poly(ADP-ribose) polymerase inhibition by olaparib.
  • [MeSH-major] Carcinoma / drug therapy. Drug Resistance, Neoplasm / genetics. Genes, BRCA1 / physiology. Genes, p53 / physiology. Mammary Neoplasms, Animal / drug therapy. Topotecan / therapeutic use


47. Ordás J, Millán Y, Dios R, Reymundo C, de Las Mulas JM: Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer; 2007;7:179
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study.
  • BACKGROUND: Feline mammary carcinoma has been proposed as a natural model of highly aggressive, hormone-independent human breast cancer.
  • METHODS: Formalin-fixed, paraffin-embedded tissue samples from 30 invasive carcinomas, 7 benign lesions and two normal mammary glands were analyzed.
  • RESULTS: Immunohistochemical HER-2 protein overexpression was found in 40% of feline mammary carcinomas, a percentage higher to that observed in human breast carcinoma.
  • However, amplification of HER-2 was detected in 16% of carcinomas with protein overexpression, a percentage much lower than that observed in their human counterpart.
  • CONCLUSION: Feline mammary carcinoma would be a suitable natural model of that subset of human breast carcinomas with HER-2 protein overexpression without gene amplification.
  • [MeSH-major] Fluorescent Dyes. In Situ Hybridization. Mammary Glands, Animal / chemistry. Mammary Neoplasms, Animal / enzymology. Mammary Neoplasms, Animal / genetics. Receptor, ErbB-2 / analysis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Nov;157(5):1467-72 [11073807.001]
  • [Cites] Adv Anat Pathol. 2000 May;7(3):158-66 [10809222.001]
  • [Cites] Breast Cancer Res Treat. 2003 Aug;80(3):363-7 [14503809.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):379-98 [14762215.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4793-8 [15269154.001]
  • [Cites] Am J Pathol. 1980 Feb;98(2):573-6 [6986788.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Mol Cell Biol. 1994 Nov;14(11):7068-77 [7935422.001]
  • [Cites] Am J Vet Res. 1996 May;57(5):693-6 [8723884.001]
  • [Cites] J Comp Pathol. 1998 Oct;119(3):263-75 [9807728.001]
  • [Cites] J Vet Med Sci. 1999 Jan;61(1):27-32 [10027159.001]
  • [Cites] Braz J Med Biol Res. 2004 Nov;37(11):1673-81 [15517084.001]
  • [Cites] Vet Pathol. 2005 Jan;42(1):30-4 [15657269.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):907-12 [15705889.001]
  • [Cites] Domest Anim Endocrinol. 2000 Jan;18(1):111-25 [10701768.001]
  • [Cites] Res Vet Sci. 2002 Apr;72(2):153-61 [12027597.001]
  • (PMID = 17880730.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fluorescent Dyes; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2045669
  •  go-up   go-down


48. Puppin C, Puglisi F, Pellizzari L, Manfioletti G, Pestrin M, Pandolfi M, Piga A, Di Loreto C, Damante G: HEX expression and localization in normal mammary gland and breast carcinoma. BMC Cancer; 2006;6:192
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HEX expression and localization in normal mammary gland and breast carcinoma.
  • BACKGROUND: The homeobox gene HEX is expressed in several cell types during different phases of animal development.
  • Aim of the present study was to evaluate the localization and the function of the protein HEX in normal and tumoral breast tissues and in breast cancer cell lines.
  • METHODS: HEX expression and nuclear localization were investigated by immunohistochemistry in normal and cancerous breast tissue, as well as in breast cancer cell lines.
  • In both ductal and lobular breast carcinomas, a great reduction of nuclear HEX was observed.
  • [MeSH-major] Breast Neoplasms / metabolism. Homeodomain Proteins / metabolism. Mammary Glands, Human / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1091-5 [10725320.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):3967-74 [15919754.001]
  • [Cites] Development. 2000 Jun;127(11):2433-45 [10804184.001]
  • [Cites] Nucleic Acids Res. 2000 Jul 1;28(13):2503-11 [10871399.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8519-24 [10890895.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Oct 5;276(3):1155-61 [11027604.001]
  • [Cites] Pediatr Res. 2000 Nov;48(5):634-8 [11044484.001]
  • [Cites] Circ Res. 2001 Jan 19;88(1):52-8 [11139473.001]
  • [Cites] Biochem J. 2001 Jun 1;356(Pt 2):297-310 [11368755.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3327-35 [11443208.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1376-83 [11889211.001]
  • [Cites] Dev Growth Differ. 2002 Aug;44(4):281-92 [12175363.001]
  • [Cites] J Cell Sci. 2002 Dec 1;115(Pt 23):4419-31 [12414989.001]
  • [Cites] EMBO J. 2003 Feb 3;22(3):689-703 [12554669.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):48-77 [12588808.001]
  • [Cites] Development. 2003 May;130(10):2039-50 [12668619.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1880-8 [12679487.001]
  • [Cites] Biochem J. 2003 Sep 15;374(Pt 3):667-75 [12826010.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6764-73 [14555989.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] Endocrinology. 2004 Mar;145(3):1290-3 [14630715.001]
  • [Cites] Nat Cell Biol. 2004 Jul;6(7):642-7 [15181450.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(18):7863-77 [15340050.001]
  • [Cites] Cell Tissue Res. 1982;227(3):563-8 [6891286.001]
  • [Cites] Am J Vet Res. 1985 Jan;46(1):287-93 [4038593.001]
  • [Cites] Mol Cell Biol. 1992 Dec;12(12):5793-800 [1448106.001]
  • [Cites] Biochim Biophys Acta. 1993 Jun 8;1154(1):65-82 [8507647.001]
  • [Cites] Development. 1998 Jan;125(1):85-94 [9389666.001]
  • [Cites] Biochem J. 1998 Apr 15;331 ( Pt 2):359-63 [9531470.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3247-51 [9745437.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Nov 9;252(1):178-83 [9813166.001]
  • [Cites] J Virol. 1999 Jan;73(1):120-7 [9847314.001]
  • [Cites] Arch Biochem Biophys. 1999 May 15;365(2):186-91 [10328811.001]
  • [Cites] J Pathol. 1999 Jan;187(1):112-26 [10341712.001]
  • [Cites] J Nutr. 2005 Jan;135(1):27-32 [15623828.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Biochim Biophys Acta. 2005 Mar 22;1743(1-2):141-50 [15777849.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4590-7 [15728128.001]
  • [Cites] BMC Cancer. 2005;5:80 [16029487.001]
  • [Cites] Development. 2000 Jun;127(11):2303-15 [10804173.001]
  • (PMID = 16854221.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HHEX protein, human; 0 / Histone Deacetylase Inhibitors; 0 / Homeodomain Proteins; 0 / Symporters; 0 / Transcription Factors; 0 / sodium-iodide symporter; 5688UTC01R / Tretinoin; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ PMC1550255
  •  go-up   go-down


49. Schug TT, Berry DC, Toshkov IA, Cheng L, Nikitin AY, Noy N: Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc Natl Acad Sci U S A; 2008 May 27;105(21):7546-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR.
  • Here, we show that, in the RA-resistant mouse model of breast cancer MMTV-neu, RA indeed activates the nonclassical RA receptor PPARbeta/delta.
  • Decreasing this ratio in mammary tissue diverted RA from PPARbeta/delta to RAR and suppressed tumor growth.

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 May 1;57(9):1668-72 [9135005.001]
  • [Cites] N Engl J Med. 1996 May 2;334(18):1150-5 [8602180.001]
  • [Cites] Curr Opin Oncol. 1999 Jan;11(1):9-13 [9914871.001]
  • [Cites] J Clin Invest. 1999 May 15;103(10):1399-408 [10330422.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):23695-8 [10446126.001]
  • [Cites] Mol Cell. 2005 Apr 29;18(3):343-53 [15866176.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8193-9 [16166294.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7889-98 [16912162.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19069-74 [17148604.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):609-15 [17234770.001]
  • [Cites] Curr Pharm Des. 2007;13(13):1375-400 [17506722.001]
  • [Cites] Cell. 2007 May 18;129(4):723-33 [17512406.001]
  • [Cites] Biochemistry. 2007 Jun 12;46(23):6744-52 [17516629.001]
  • [Cites] Cancer Lett. 2007 Aug 8;253(1):14-24 [17188427.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):959-65 [17554340.001]
  • [Cites] J Mol Biol. 2007 Oct 5;372(5):1246-60 [17761196.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1797-815 [10669755.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):968-88 [10713680.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6403-8 [10823918.001]
  • [Cites] Oncogene. 2000 Aug 17;19(35):4066-70 [10962564.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28488-93 [10862772.001]
  • [Cites] J Mol Biol. 2001 Jan 26;305(4):939-49 [11162104.001]
  • [Cites] Histol Histopathol. 2001 Jul;16(3):909-22 [11510982.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3263-77 [11751632.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2632-41 [11909957.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5114-27 [12077340.001]
  • [Cites] Oncogene. 2002 Aug 8;21(34):5224-32 [12149644.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5134-8 [12234974.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4426-33 [12907615.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):41589-92 [12963727.001]
  • [Cites] Expert Opin Ther Targets. 2004 Feb;8(1):39-48 [14996617.001]
  • [Cites] J Invest Dermatol. 2004 Apr;122(4):971-83 [15102088.001]
  • [Cites] Annu Rev Nutr. 2004;24:201-21 [15189119.001]
  • [Cites] Cancer Res. 1982 Sep;42(9):3519-25 [6286109.001]
  • [Cites] Science. 1985 Sep 6;229(4717):974-6 [2992089.001]
  • [Cites] Lancet. 1986 Apr 5;1(8484):765-7 [2870269.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Am J Pathol. 1991 Sep;139(3):495-501 [1887859.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82 [1359541.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(3):151-9 [7902172.001]
  • [Cites] Development. 1995 Feb;121(2):539-48 [7768191.001]
  • [Cites] J Biol Chem. 1995 Nov 3;270(44):26116-22 [7592814.001]
  • [Cites] J Histochem Cytochem. 1998 Oct;46(10):1103-11 [9742066.001]
  • (PMID = 18495924.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / K26 RR017595; United States / NCI NIH HHS / CA / 5T32CA009682; United States / NCI NIH HHS / CA / R01 CA96823; United States / NCI NIH HHS / CA / R01 CA096823; United States / NCI NIH HHS / CA / T32 CA009682; United States / NCI NIH HHS / CA / R01 CA107013
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fabp5 protein, mouse; 0 / Fatty Acid-Binding Proteins; 0 / Neoplasm Proteins; 0 / PPAR delta; 0 / PPAR-beta; 0 / Receptors, Retinoic Acid; 0 / retinoic acid binding protein II, cellular; 5688UTC01R / Tretinoin
  • [Other-IDs] NLM/ PMC2396692
  •  go-up   go-down


50. Simeonov R, Simeonova G: Nuclear cytomorphometry in feline mammary gland epithelial tumours. Vet J; 2009 Feb;179(2):296-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear cytomorphometry in feline mammary gland epithelial tumours.
  • Stained cytological specimens from 35 feline mammary gland epithelial tumours (4 adenomas, 11 tubulopapillary carcinomas 13 solid carcinomas and 7 cribriform carcinomas) were analysed by computer-assisted nuclear morphometry.
  • The study aimed to evaluate (1) the possibility of using nuclear cytomorphometry as an auxiliary diagnostic method to differentiate between benign and malignant feline mammary gland epithelial tumours, and (2) the prognostic value of nuclear morphometry in feline mammary carcinomas.
  • The results indicated that MNA, MNP, MND and NR could be a useful adjunct in diagnosis but are not reliable prognostic indicators for feline mammary gland carcinomas.
  • [MeSH-major] Cat Diseases / diagnosis. Cell Nucleus / pathology. Cytological Techniques / veterinary. Mammary Glands, Animal / cytology. Mammary Neoplasms, Animal / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Adenoma / veterinary. Animals. Automation. Carcinoma / diagnosis. Carcinoma / pathology. Carcinoma / veterinary. Cats. Diagnosis, Differential. Female

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17959399.001).
  • [ISSN] 1090-0233
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Umesako S, Fujisawa K, Iiga S, Mori N, Takahashi M, Hong DP, Song CW, Haga S, Imai S, Niwa O, Okumoto M: Atm heterozygous deficiency enhances development of mammary carcinomas in p53 heterozygous knockout mice. Breast Cancer Res; 2005;7(1):R164-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atm heterozygous deficiency enhances development of mammary carcinomas in p53 heterozygous knockout mice.
  • Although ataxia-telangiectasia mutated (ATM) heterozygous deficiency has been proposed to increase susceptibility to breast cancer, some studies have not found excess risk.
  • In experimental animals, increased susceptibility to breast cancer is not observed in the Atm heterozygous deficient mice (Atm+/-) carrying a knockout null allele.
  • In order to determine the effect of Atm heterozygous deficiency on mammary tumourigenesis, we generated a series of Atm+/- mice on the p53+/- background with a certain predisposition to spontaneous development of mammary carcinomas, and we examined the development of the tumours after X-irradiation.
  • RESULTS: We tested the effect of haploinsufficiency of the Atm gene on mammary tumourigenesis after X-irradiation in the p53+/- mice of the BALB/cHeA x MSM/Ms background.
  • The singly heterozygous p53+/- mice subjected to X-irradiation developed mammary carcinomas at around 25 weeks of age, and the final incidence of mammary carcinomas at 39 weeks was 31% (19 out of 61).
  • The introduction of the heterozygous Atm knockout alleles into the background of the p53+/- genotype significantly increased the incidence of mammary carcinoma to 58% (32 out of 55) and increased the average number of mammary carcinomas per mouse.
  • However, introduction of Atm alleles did not change the latency of development of mammary carcinoma.
  • CONCLUSION: Our results indicate a strong enhancement in mammary carcinogenesis by Atm heterozygous deficiency in p53+/- mice.
  • Thus, doubly heterozygous mice represent a useful model system with which to analyze the interaction of heterozygous genotypes for p53, Atm and other genes, and their effects on mammary carcinogenesis.
  • [MeSH-major] Carcinoma / genetics. Carcinoma / physiopathology. Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Genes, p53. Mammary Neoplasms, Animal / genetics. Mammary Neoplasms, Animal / physiopathology. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / genetics

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Genet Metab. 1999 Dec;68(4):419-23 [10607471.001]
  • [Cites] Oncogene. 1999 Jul 22;18(29):4282-5 [10435642.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):2151-9 [11106587.001]
  • [Cites] J Natl Cancer Inst. 2001 Jan 17;93(2):121-7 [11208881.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):288-93 [11410879.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):479-87 [11505391.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6577-82 [11522657.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):185-90 [12195425.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):89-90 [12205473.001]
  • [Cites] J Radiat Res. 2002 Jun;43(2):175-85 [12238332.001]
  • [Cites] Breast Cancer Res. 2002;4(6):249-52 [12473172.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Sep;145(2):115-20 [12935922.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7263-9 [14612522.001]
  • [Cites] J Radiat Res. 2003 Sep;44(3):249-54 [14646229.001]
  • [Cites] N Engl J Med. 1987 May 21;316(21):1289-94 [3574400.001]
  • [Cites] Cancer Res. 1990 Jul 1;50(13):3848-50 [2354437.001]
  • [Cites] N Engl J Med. 1991 Dec 26;325(26):1831-6 [1961222.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):66-9 [7987394.001]
  • [Cites] Cell. 1996 Jul 12;86(1):159-71 [8689683.001]
  • [Cites] Nat Genet. 1997 Mar;15(3):307-10 [9054948.001]
  • [Cites] Annu Rev Immunol. 1997;15:177-202 [9143686.001]
  • [Cites] Nat Genet. 1997 Aug;16(4):397-401 [9241281.001]
  • [Cites] Oncogene. 1998 May 28;16(21):2747-54 [9652741.001]
  • [Cites] Mol Carcinog. 1998 Jul;22(3):175-81 [9688143.001]
  • [Cites] Nature. 1998 Nov 12;396(6707):177-80 [9823898.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1304-7 [10098776.001]
  • [Cites] Nat Genet. 1999 Apr;21(4):359-60 [10192382.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):968-88 [10713680.001]
  • (PMID = 15642165.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC1064114
  •  go-up   go-down


52. Hatina J, Ruzicka T: [Relevance of cell culture models in cutaneous tumour biology. Part I: tumour cell lines]. Hautarzt; 2008 Jan;59(1):36-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous squamous cell carcinoma, basal cell carcinoma and melanoma, much like all other human solid tumors, result from a multi-step process in which genetic and epigenetic changes accumulate in the affected cells.
  • While for most studies, human transformed cell lines are the model of choice, there are questions for which animal cell lines are strongly preferred, such as interactions between the tumor and the immune system.
  • [MeSH-major] Cell Line, Tumor / pathology. Cell Line, Tumor / physiology. Disease Models, Animal. Skin Neoplasms / pathology. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Jan 8;23(1):30-8 [14712208.001]
  • [Cites] Annu Rev Pathol. 2007;2:175-89 [18039097.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):441-52 [10433937.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):159-67 [10623663.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;995:151-61 [12814947.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 15;142(2):87-91 [12699882.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7147-57 [14612508.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4359-70 [9494534.001]
  • [Cites] Mol Carcinog. 1998 Nov;23(3):144-58 [9833775.001]
  • [Cites] J Surg Res. 1995 Feb;58(2):165-74 [7861768.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3075-86 [8674065.001]
  • [Cites] Cancer Res. 1990 Apr 15;50(8):2296-302 [2156614.001]
  • [Cites] J Cell Biochem. 1994 Feb;54(2):161-73 [8175891.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Exp Dermatol. 2007 Apr;16(4):297-301 [17359335.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):365-78 [14973382.001]
  • [Cites] Exp Dermatol. 2000 Apr;9(2):104-17 [10772384.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1567-79 [11583982.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:339-73 [16824012.001]
  • [Cites] Arch Dermatol. 1996 Oct;132(10):1185-93 [8859029.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1372-7 [16470173.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4320-33 [15899824.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):1026-36 [12821146.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5670-6 [4053039.001]
  • [Cites] J Invest Dermatol. 2005 Feb;124(2):401-4 [15675960.001]
  • [Cites] Exp Cell Res. 2000 Aug 1;258(2):352-60 [10896786.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):935-46 [17320377.001]
  • [Cites] J Dtsch Dermatol Ges. 2005 Jul;3(7):493-503 [15967008.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2205-11 [2009539.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2840-7 [2183932.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):875-9 [8631027.001]
  • [Cites] Dtsch Med Wochenschr. 2007 Aug;132(31-32):1629-32 [17654417.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1214-6 [16702970.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3759-65 [12097286.001]
  • [Cites] Cancer Res. 1980 May;40(5):1636-44 [7370995.001]
  • [Cites] Histol Histopathol. 2002;17 (3):951-9 [12168807.001]
  • [Cites] J Invest Dermatol. 2000 Dec;115(6):1095-103 [11121147.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S35-42 [9578415.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3837-44 [12881305.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Invest Dermatol. 2005 Feb;124(2):457-65 [15675968.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3112-7 [8674069.001]
  • [Cites] Prostate. 1986;9(3):261-81 [3774632.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5270-82 [15289333.001]
  • [Cites] Schweiz Med Wochenschr. 2000 Apr 29;130(17):617-24 [10829299.001]
  • [Cites] Hautarzt. 2004 Oct;55(10):942-51 [15349693.001]
  • [Cites] Pathologe. 1994 Jun;15(3):141-9 [8072948.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):976-81 [12439909.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):668-75 [7532159.001]
  • [Cites] Nat Med. 1997 Jul;3(7):788-92 [9212109.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • (PMID = 18058078.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 64
  •  go-up   go-down


53. Behling-Kelly E, Petersen S, Muthuswamy A, Webb JL, Young KM: Neoplastic pleocytosis in a dog with metastatic mammary carcinoma and meningeal carcinomatosis. Vet Clin Pathol; 2010 Jun;39(2):247-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic pleocytosis in a dog with metastatic mammary carcinoma and meningeal carcinomatosis.
  • Approximately 1 year before presentation, multiple mammary cysts had been surgically excised.
  • A mammary mass was noted on physical examination, and 2 separate parenchymal brain lesions were found on imaging studies.
  • The dog was euthanized, and on necropsy a primary solid mammary carcinoma was identified as well as multiple metastatic foci in the brain with diffuse meningeal involvement.
  • The cells in the CSF had a morphologic appearance similar to the cells in the primary mammary tumor and in the metastatic tumors in the brain.
  • On immunostaining, cells from the primary mammary tumor, the brain tumors, and the CSF expressed cytokeratin.
  • A final diagnosis of mammary carcinoma with brain metastasis and meningeal carcinomatosis was made.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20070645.001).
  • [ISSN] 1939-165X
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. McNeill CJ, Sorenmo KU, Shofer FS, Gibeon L, Durham AC, Barber LG, Baez JL, Overley B: Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma. J Vet Intern Med; 2009 Jan-Feb;23(1):123-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma.
  • BACKGROUND: Feline mammary carcinomas (FMC) are locally invasive and highly metastatic tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175730.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


55. Kaufmann Y, Spring P, Klimberg VS: Oral glutamine prevents DMBA-induced mammary carcinogenesis via upregulation of glutathione production. Nutrition; 2008 May;24(5):462-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral glutamine prevents DMBA-induced mammary carcinogenesis via upregulation of glutathione production.
  • Previously we demonstrated that supplemental glutamine inhibited tumor growth in an implantable tumor model and 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral squamous cell carcinoma model; these reductions were associated with enhancing NK cell cytotoxicity, blood glutathione levels, and/or gut glutathione release.
  • Therefore, we hypothesized that oral glutamine might suppress DMBA-induced mammary carcinogenesis by upregulation of glutathione production and/or augmentation of NK cell activity.
  • [MeSH-major] Glutamine / administration & dosage. Glutathione / metabolism. Killer Cells, Natural / metabolism. Mammary Neoplasms, Experimental / prevention & control. Up-Regulation
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Administration, Oral. Animals. Disease Models, Animal. Female. Random Allocation. Rats. Rats, Sprague-Dawley. Time Factors

  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313901.001).
  • [ISSN] 0899-9007
  • [Journal-full-title] Nutrition (Burbank, Los Angeles County, Calif.)
  • [ISO-abbreviation] Nutrition
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0RH81L854J / Glutamine; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; GAN16C9B8O / Glutathione
  •  go-up   go-down


56. Houghton J, Li H, Fan X, Liu Y, Liu JH, Rao VP, Poutahidis T, Taylor CL, Jackson EA, Hewes C, Lyle S, Cerny A, Bowen G, Cerny J, Moore N, Kurt-Jones EA, Erdman SE: Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev; 2010 Aug;19(8):1153-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address this question, Apc(Min/+) and Apc(Min/+) Rag2(-/-) mice, which have a predilection to mammary carcinoma (as well as wild-type (wt) mice), received mesenchymal stem cells (MSC) with mutant p53 (p53MSC) transferred via tail vein injection.
  • No mammary tumors were found.
  • However, in mice carrying the Apc(Min/+) mutation, p53MSC homed to mammary tissue and significantly increased the incidence of mammary carcinoma.
  • The increased cancer phenotype was completely preventable with neutralization of TNF-alpha or by transfer of CD4(+) regulatory T cells from immune competent donors, demonstrating that immune competency to regulate inflammation was sufficient to maintain neoplastic dormancy even in the presence of oncogenic epithelial and stromal mutations.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Genet Dev. 2000 Feb;10(1):120-7 [10679388.001]
  • [Cites] Nature. 2009 Aug 27;460(7259):1140-4 [19668186.001]
  • [Cites] J Nephrol. 2000 Nov-Dec;13 Suppl 3:S111-20 [11132027.001]
  • [Cites] Cell. 2001 May 4;105(3):369-77 [11348593.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):41-9 [12077603.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):341-50 [12163453.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):991-8 [12407406.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):355-7 [12379854.001]
  • [Cites] J Exp Med. 2003 Jan 6;197(1):111-9 [12515818.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):691-702 [12547727.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1030-1 [12586934.001]
  • [Cites] Stem Cells. 2003;21(5):514-20 [12968105.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6042-50 [14522933.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):787 [14985739.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1495-502 [14996910.001]
  • [Cites] Annu Rev Immunol. 2004;22:329-60 [15032581.001]
  • [Cites] J Cell Sci. 1998 Feb;111 ( Pt 4):443-53 [9443894.001]
  • [Cites] Histopathology. 1999 Sep;35(3):249-56 [10469217.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8492-5 [15574751.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1627-30 [15753354.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):207-8 [15766657.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3035-9 [15833829.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3200-8 [15833851.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3998-4004 [15899788.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1984-95 [15940631.001]
  • [Cites] Nature. 2009 Aug 27;460(7259):1149-53 [19668189.001]
  • [Cites] Nature. 2009 Aug 27;460(7259):1132-5 [19668191.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):5095-8 [15107831.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):509-17 [15349825.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7366-77 [15326482.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):531-8 [2408737.001]
  • [Cites] Br J Cancer. 1987 Dec;56(6):814-9 [2829956.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):381-5 [2910445.001]
  • [Cites] Lab Invest. 1993 Jun;68(6):696-707 [8515656.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1061-4 [7576992.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Cell. 2005 Dec 16;123(6):985-7 [16360028.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1001-11 [16360031.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):57-61 [16397216.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):69-75 [16680573.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7395-400 [16885333.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):409-16 [16951987.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):622-9 [17311302.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10889-98 [18006834.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):903-7 [18026089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19977-82 [18077429.001]
  • [Cites] N Engl J Med. 2007 Dec 20;357(25):2543-51 [18094375.001]
  • [Cites] N Engl J Med. 2008 Apr 10;358(15):1634-5; author reply 1636 [18403774.001]
  • [Cites] N Engl J Med. 2008 Apr 10;358(15):1635-6; author reply 1636 [18411429.001]
  • [Cites] N Engl J Med. 2008 Apr 10;358(15):1635; author reply 1636 [18411430.001]
  • [Cites] Gene Ther. 2008 May;15(10):730-8 [18401438.001]
  • [Cites] Carcinogenesis. 2000 Jul;21(7):1453-6 [10874025.001]
  • (PMID = 20199238.001).
  • [ISSN] 1557-8534
  • [Journal-full-title] Stem cells and development
  • [ISO-abbreviation] Stem Cells Dev.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI051405; United States / NCI NIH HHS / CA / R01CA119061; United States / NCI NIH HHS / CA / R01 CA119061; United States / NIEHS NIH HHS / ES / P30 ES002109; United States / NCI NIH HHS / CA / R01 CA108854; United States / NIAID NIH HHS / AI / R01 AI51405; United States / NCI NIH HHS / CA / R01CA108854
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Culture Media, Conditioned; 0 / DNA-Binding Proteins; 0 / Rag2 protein, mouse; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC3135253
  •  go-up   go-down


57. Pinho SS, Reis CA, Gärtner F, Alpaugh ML: Molecular plasticity of E-cadherin and sialyl lewis x expression, in two comparative models of mammary tumorigenesis. PLoS One; 2009;4(8):e6636
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular plasticity of E-cadherin and sialyl lewis x expression, in two comparative models of mammary tumorigenesis.
  • METHODOLOGY: Our study analyzed the expression of two adhesion molecules, E-cadherin and Sialyl Lewis x (sLe(x)), in both a canine mammary carcinoma and human inflammatory breast cancer (IBC) model, using double labelled immunofluorescence staining.
  • RESULTS: Our results demonstrate that canine mammary carcinoma and human IBC exhibit an inversely correlated cellular expression of E-cadherin and sLe(x) within the same tumor embolus.
  • [MeSH-major] Cadherins / metabolism. Disease Models, Animal. Mammary Neoplasms, Experimental / metabolism. Oligosaccharides / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5079-84 [10537277.001]
  • [Cites] Radiol Technol. 2008 Sep;80(1):49M-60M; quiz 61M-63M [18796566.001]
  • [Cites] Breast Cancer Res. 2000;2(5):321-3 [11250723.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5231-41 [11431364.001]
  • [Cites] Oncogene. 2002 May 16;21(22):3631-43 [12032865.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):619-28 [12163386.001]
  • [Cites] Breast Cancer Res. 2003;5(2):101-6 [12631389.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(2):141-8 [12725414.001]
  • [Cites] Glycoconj J. 2004;20(3):189-98 [15090732.001]
  • [Cites] Cancer Sci. 2004 May;95(5):377-84 [15132763.001]
  • [Cites] Breast Cancer Res. 2004;6(4):R300-7 [15217496.001]
  • [Cites] Invest Cell Pathol. 1979 Oct-Dec;2(4):257-75 [396282.001]
  • [Cites] Cell. 1991 Jan 25;64(2):327-36 [1703045.001]
  • [Cites] J Reprod Fertil Suppl. 1993;47:489-99 [8229968.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1529-37 [9362419.001]
  • [Cites] Nature. 2007 Apr 26;446(7139):1023-9 [17460663.001]
  • [Cites] Lancet. 2007 May 19;369(9574):1742-57 [17512859.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):816-29 [17243120.001]
  • [Cites] BMC Cancer. 2007;7:124 [17617904.001]
  • [Cites] Nat Cell Biol. 2007 Sep;9(9):1016-24 [17762893.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11471-5 [18089772.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11476-9; discussion 11479-80 [18089773.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):147-56 [18202698.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(13 Spec No):1607-20 [10959047.001]
  • (PMID = 19675678.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; 0 / Cadherins; 0 / Oligosaccharides
  • [Other-IDs] NLM/ PMC2722091
  •  go-up   go-down


58. Orsolic N, Sver L, Terzić S, Basić I: Peroral application of water-soluble derivative of propolis (WSDP) and its related polyphenolic compounds and their influence on immunological and antitumour activity. Vet Res Commun; 2005 Oct;29(7):575-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the effect of propolis and polyphenolic compounds, components of propolis, on the growth and metastatic potential of a transplantable mammary carcinoma (MCa) of the mouse.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacology. Flavonoids / administration & dosage. Flavonoids / pharmacology. Mammary Neoplasms, Experimental / drug therapy. Phenols / administration & dosage. Phenols / pharmacology. Propolis / analogs & derivatives

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1963 Apr 26;140(3565):405 [17815805.001]
  • [Cites] J Immunol Methods. 1994 Jun 3;172(1):1-16 [8207258.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1255-61 [7680281.001]
  • [Cites] Nutr Cancer. 2000;37(2):179-86 [11142091.001]
  • [Cites] Nutr Cancer. 2001;41(1-2):107-10 [12094612.001]
  • [Cites] J Immunol. 1977 Jan;118(1):77-82 [137265.001]
  • [Cites] J R Soc Med. 1990 Mar;83(3):159-60 [2182860.001]
  • [Cites] Annu Rev Immunol. 1997;15:323-50 [9143691.001]
  • [Cites] Cancer Detect Prev. 1998;22(6):506-15 [9824373.001]
  • [Cites] J Leukoc Biol. 1998 Sep;64(3):275-90 [9738653.001]
  • [Cites] Vaccine. 1992;10(12):817-23 [1455907.001]
  • [Cites] Chem Res Toxicol. 1997 Dec;10(12):1296-313 [9437518.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3B):1665-71 [11497245.001]
  • [Cites] Anal Biochem. 1975 Sep;68(1):230-5 [1190437.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):1841-8 [8572568.001]
  • [Cites] J Exp Med. 1989 May 1;169(5):1543-55 [2497225.001]
  • [Cites] J Exp Med. 1977 Nov 1;146(5):1420-35 [303681.001]
  • [Cites] Experientia. 1988 Mar 15;44(3):230-2 [2450776.001]
  • [Cites] J Ethnopharmacol. 2003 Feb;84(2-3):265-73 [12648825.001]
  • [Cites] Eur J Immunol. 1996 Jun;26(6):1308-13 [8647210.001]
  • [Cites] Drug Metabol Drug Interact. 2000;17(1-4):311-49 [11201302.001]
  • [Cites] Anticancer Res. 1995 May-Jun;15(3):703-7 [7645946.001]
  • (PMID = 16142606.001).
  • [ISSN] 0165-7380
  • [Journal-full-title] Veterinary research communications
  • [ISO-abbreviation] Vet. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Blood Proteins; 0 / Flavonoids; 0 / Mitogens; 0 / Phenols; 0 / Polyphenols; 31C4KY9ESH / Nitric Oxide; 9009-62-5 / Propolis
  •  go-up   go-down


59. Antuofermo E, Miller MA, Pirino S, Xie J, Badve S, Mohammed SI: Spontaneous mammary intraepithelial lesions in dogs--a model of breast cancer. Cancer Epidemiol Biomarkers Prev; 2007 Nov;16(11):2247-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous mammary intraepithelial lesions in dogs--a model of breast cancer.
  • Mammary intraepithelial lesions (IEL) are nowadays frequently diagnosed as a result of the success of mammographic screening, education programs, and awareness by women.
  • Establishment of an animal model for these lesions to test treatment or preventive modalities is a prerequisite for human clinical trials.
  • This study describes the histologic and immunohistochemical similarity between human and canine mammary IELs.
  • Mammary tumors from 200 dogs were classified and histologic sections of the excisional specimens were evaluated for IELs.
  • IELs, found in specimens from 60 dogs, were categorized as adenosis, sclerosing adenosis, intraductal papilloma, sclerosing papilloma, ductal hyperplasia, atypical ductal hyperplasia (ADH), and ductal carcinoma in situ (DCIS; high, intermediate, and low grade).
  • Most proliferative IELs without atypia were associated with benign tumors, whereas IELs with atypia (ADH and DCIS) were generally associated with mammary cancer.
  • Canine mammary IELs were strikingly similar to those of the human breast.
  • The frequency of IELs in the dog, their association with spontaneous mammary cancer, their pattern of ER-alpha and HER-2 expression, and their histologic resemblance to human IELs may make the dog an ideal model to study human ER-negative (both HER-2 positive and negative) breast cancer progression as well as prevention and treatment.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma in Situ / veterinary. Dog Diseases / pathology. Mammary Neoplasms, Animal / pathology
  • [MeSH-minor] Animals. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Disease Models, Animal. Dogs. Estrogen Receptor alpha / biosynthesis. Female. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Receptor, ErbB-2 / biosynthesis. Receptors, Progesterone / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2181-3 [17982116.001]
  • (PMID = 17982119.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Ki-67 Antigen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


60. Yang M, Jiang P, Hoffman RM: Whole-body subcellular multicolor imaging of tumor-host interaction and drug response in real time. Cancer Res; 2007 Jun 1;67(11):5195-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To noninvasively image cancer cell/stromal cell interaction in the tumor microenvironment and drug response at the cellular level in live animals in real time, we developed a new imageable three-color animal model.
  • The model consists of green fluorescent protein (GFP)-expressing mice transplanted with dual-color cancer cells labeled with GFP in the nucleus and red fluorescent protein in the cytoplasm.
  • The Olympus IV100 Laser Scanning Microscope, with ultra-narrow microscope objectives ("stick objectives"), is used for three-color whole-body imaging of the two-color cancer cells interacting with the GFP-expressing stromal cells.
  • In this model, drug response of both cancer and stromal cells in the intact live animal is also imaged in real time.
  • This new model system enables the first cellular and subcellular images of unperturbed tumors in the live intact animal.
  • New visible real-time targets for novel anticancer agents are provided in this model, including the color-coded interacting cancer and stromal cells, tumor vasculature, and blood flow.
  • This imageable model should lead to many new insights of in vivo cancer cell biology and to novel drug discovery.
  • [MeSH-major] Carcinoma, Lewis Lung / drug therapy. Carcinoma, Lewis Lung / pathology. Image Processing, Computer-Assisted / methods. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / pathology. Microscopy, Confocal / methods
  • [MeSH-minor] Animals. Disease Models, Animal. Doxorubicin / pharmacology. Female. Green Fluorescent Proteins / analysis. Green Fluorescent Proteins / biosynthesis. Green Fluorescent Proteins / genetics. Histones / genetics. Luminescent Proteins / analysis. Luminescent Proteins / biosynthesis. Luminescent Proteins / genetics. Male. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Nude. Mice, Transgenic. NIH 3T3 Cells. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Subcellular Fractions / metabolism. Transduction, Genetic

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545599.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA099258; United States / NCI NIH HHS / CA / CA103563
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 0 / Luminescent Proteins; 0 / red fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; 80168379AG / Doxorubicin
  •  go-up   go-down


61. Wensman H, Heldin NE, Pejler G, Hellmén E: Diverse bone morphogenetic protein expression profiles and smad pathway activation in different phenotypes of experimental canine mammary tumors. PLoS One; 2009;4(9):e7133
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diverse bone morphogenetic protein expression profiles and smad pathway activation in different phenotypes of experimental canine mammary tumors.
  • Currently, most BMP expression studies are performed on carcinomas, and not much is known about the situation in sarcomas.
  • METHODOLOGY/PRINCIPAL FINDINGS: We have investigated the BMP expression profiles and Smad activation in clones from different spontaneous canine mammary tumors.
  • Clones from a scirrhous carcinoma expressed much lower BMP levels.
  • Phosphorylated Smad-1/5, located in the nucleus, was detected in tumors derived from clones expressing high levels of BMPs, indicating an active BMP signaling pathway and BMP-2 stimulation of mammary tumor cell clones in vitro resulted in activation of the Smad-1/5 pathway.
  • CONCLUSIONS/SIGNIFICANCE: We conclude that the specific BMP expression repertoire differs substantially between different types of mammary tumors and that BMP-6 expression most probably has a biological role in bone formation of canine mammary tumors.
  • [MeSH-minor] Animals. Cell Line, Tumor. Dogs. Eye Proteins / metabolism. Female. Mammary Neoplasms, Animal. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Neoplasms, Experimental / metabolism. Nerve Tissue Proteins / metabolism. Phenotype. Transforming Growth Factor beta / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2000 Jun;61(3):197-210 [10965996.001]
  • [Cites] J Cell Physiol. 1998 Nov;177(2):355-63 [9766532.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 20;285(3):773-81 [11453659.001]
  • [Cites] Vet Pathol. 2001 Nov;38(6):703-9 [11732805.001]
  • [Cites] Dev Biol. 2001 Nov 1;239(1):1-14 [11784015.001]
  • [Cites] Science. 2002 May 31;296(5573):1646-7 [12040180.001]
  • [Cites] J Pathol. 2005 Jul;206(3):366-76 [15892165.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):949-52 [16175182.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35704-12 [16109715.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Apr;45(4):411-9 [16419056.001]
  • [Cites] J Cell Biochem. 2006 Jun 1;98(3):538-54 [16317727.001]
  • [Cites] Exp Eye Res. 2006 Nov;83(5):1162-70 [16879818.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jun;103(2):239-46 [17004110.001]
  • [Cites] J Cell Biochem. 2008 Apr 1;103(5):1584-97 [17879955.001]
  • [Cites] Vet Pathol. 2008 Nov;45(6):803-15 [18984783.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):589-600 [17165130.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1867-71 [12154118.001]
  • [Cites] Mol Ther. 2002 Oct;6(4):464-70 [12377187.001]
  • [Cites] Endocr Rev. 2002 Dec;23(6):787-823 [12466190.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):277-81 [12543773.001]
  • [Cites] J Bone Joint Surg Am. 2003 Aug;85-A(8):1544-52 [12925636.001]
  • [Cites] Vet Pathol. 2004 Mar;41(2):154-63 [15017029.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):3024-32 [14691444.001]
  • [Cites] J Orthop Sci. 2004;9(3):334-40 [15168194.001]
  • [Cites] Stem Cells Dev. 2004 Jun;13(3):273-80 [15186723.001]
  • [Cites] Gene Ther. 2004 Sep;11(17):1312-20 [15269709.001]
  • [Cites] Prog Growth Factor Res. 1989;1(4):267-80 [2491264.001]
  • [Cites] Endocrinology. 1991 Oct;129(4):2187-93 [1655394.001]
  • [Cites] J Comp Pathol. 1995 Nov;113(4):327-42 [8746956.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] FEBS Lett. 1998 Aug 28;434(1-2):83-7 [9738456.001]
  • [Cites] Dev Biol. 2001 Apr 15;232(2):372-87 [11401399.001]
  • (PMID = 19771160.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Morphogenetic Proteins; 0 / CHRDL1 protein, human; 0 / Eye Proteins; 0 / Nerve Tissue Proteins; 0 / Smad Proteins; 0 / Transforming Growth Factor beta; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2740828
  •  go-up   go-down


62. Palha De Sousa C, Blum CM, Sgroe EP, Crespo AM, Kurt RA: Murine mammary carcinoma cells and CD11c(+) dendritic cells elicit distinct responses to lipopolysaccharide and exhibit differential expression of genes required for TLR4 signaling. Cell Immunol; 2010;266(1):67-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Murine mammary carcinoma cells and CD11c(+) dendritic cells elicit distinct responses to lipopolysaccharide and exhibit differential expression of genes required for TLR4 signaling.
  • Because the majority of cancers are carcinomas, and thus of epithelial origin, we wanted to know whether a carcinoma and DC responded similarly to a TLR agonist.
  • We found the mammary carcinoma 4T1 and CD11c(+) DC both secreted proinflammatory chemokines in response to the TLR4 agonist lipopolysaccharide (LPS).
  • Despite the low level of TLR signaling proteins, the carcinoma were able to elicit a range of responses contingent upon the source, dose, length, and frequency of TLR agonist treatment.
  • Thus, carcinoma and DC are distinctly responsive to LPS.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Blood. 2003 Sep 1;102(5):1740-2 [12714497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3372-7 [17360653.001]
  • [Cites] Br J Cancer. 1973 May;27(5):370-89 [4713170.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4325-33 [10485480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16274-9 [15534227.001]
  • [Cites] J Immunol. 2005 Feb 1;174(3):1507-12 [15661910.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5491-5 [15623538.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5009-14 [15958541.001]
  • [Cites] World J Gastroenterol. 2005 Oct 28;11(40):6330-7 [16419162.001]
  • [Cites] Annu Rev Immunol. 2006;24:353-89 [16551253.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):816-25 [16410796.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):7959-67 [17114468.001]
  • [Cites] Cardiovasc Res. 2007 Jan 1;73(1):181-9 [17156768.001]
  • [Cites] Infect Immun. 2007 Mar;75(3):1280-90 [17178782.001]
  • [Cites] Nat Rev Immunol. 2007 Mar;7(3):179-90 [17318230.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11058-63 [10753909.001]
  • [Cites] J Surg Res. 2001 May 1;97(1):14-9 [11319874.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(1-2):133-43 [11831642.001]
  • [Cites] Int Immunol. 2003 Apr;15(4):491-503 [12663679.001]
  • [Cites] Blood. 2007 May 1;109(9):3890-4 [17218388.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 May;292(5):F1471-8 [17299140.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):168-80 [18176598.001]
  • [Cites] Exp Dermatol. 2008 Feb;17(2):100-7 [18031543.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1462-70 [18316610.001]
  • [Cites] J Immunol. 2008 Mar 15;180(6):4308-15 [18322244.001]
  • [Cites] J Immunol. 2008 Apr 1;180(7):4371-81 [18354157.001]
  • [Cites] Immunol Lett. 2008 Jun 15;118(1):30-5 [18403024.001]
  • [Cites] Transplantation. 2008 Jul 15;86(1):1-9 [18622268.001]
  • [Cites] J Immunol. 2008 Aug 1;181(3):1849-58 [18641322.001]
  • [Cites] Oncologist. 2008 Aug;13(8):859-75 [18701762.001]
  • [Cites] Vaccine. 2008 Oct 16;26(44):5554-61 [18722493.001]
  • [Cites] Int J Colorectal Dis. 2009 Feb;24(2):231-7 [19050899.001]
  • [Cites] J Hepatol. 2009 Dec;51(6):1037-45 [19716616.001]
  • [Cites] Circulation. 2009 Dec 15;120(24):2462-9 [19948979.001]
  • [Cites] Eur J Immunol. 2004 Oct;34(10):2863-73 [15368303.001]
  • (PMID = 20869044.001).
  • [ISSN] 1090-2163
  • [Journal-full-title] Cellular immunology
  • [ISO-abbreviation] Cell. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R15 CA137858; United States / NCI NIH HHS / CA / R15 CA137858-01; United States / NCI NIH HHS / CA / R15CA137858
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD11c; 0 / Antigens, CD14; 0 / Chemokines; 0 / Cytokines; 0 / Intracellular Signaling Peptides and Proteins; 0 / Lipopolysaccharides; 0 / Myd88 protein, mouse; 0 / Myeloid Differentiation Factor 88; 0 / Peptidoglycan; 0 / Receptors, Interleukin; 0 / TIRP protein, mouse; 0 / Tlr2 protein, mouse; 0 / Tlr4 protein, mouse; 0 / Toll-Like Receptor 2; 0 / Toll-Like Receptor 4
  • [Other-IDs] NLM/ NIHMS240517; NLM/ PMC2966517
  •  go-up   go-down


63. Burrai GP, Mohammed SI, Miller MA, Marras V, Pirino S, Addis MF, Uzzau S, Antuofermo E: Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer; 2010;10:156
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions.
  • BACKGROUND: Breast cancer is the most frequently diagnosed cancer in women.
  • Intraepithelial lesions (IELs), such as usual ductal hyperplasia (UH), atypical ductal hyperplasia (ADH), and ductal carcinoma in situ (DCIS) are risk factors that predict a woman's chance of developing invasive breast cancer.
  • Therefore, a comparative study that establishes an animal model of pre-invasive lesions is needed for the development of preventative measures and effective treatment for both mammary IELs and tumors.
  • The purpose of this study was to characterize the histologic and molecular features of feline mammary IELs and compare them with those in women.
  • METHODS: Formalin-fixed, paraffin-embedded specimens (n = 205) from 203 female cats with clinical mammary disease were retrieved from the archives of the Purdue University Animal Disease Diagnostic Laboratory and Veterinary Teaching Hospital (West Lafayette, IN), and the Department of Pathology and Veterinary Clinic, School of Veterinary Medicine (Sassari, Italy).
  • Histologic sections, stained with hematoxylin and eosin (HE), were evaluated for the presence of IELs in tissue adjacent to excised mammary tumors.
  • RESULTS: Intraepithelial lesions were found in 57 of 203 (28%) feline mammary specimens and were categorized as UH (27%), ADH (29%), and DCIS (44%).
  • Most IELs with atypia (ADH and DCIS) were associated with mammary cancer (91%), whereas UH was associated with benign lesions in 53% of cases.
  • CONCLUSION: The remarkable similarity of feline mammary IELs to those of humans, with the tendency to lose hormone receptor expression in atypical IELs, supports the cat as a possible model to study ER- and PR-negative breast lesions.
  • [MeSH-major] Breast Neoplasms / pathology. Disease Models, Animal. Estrogen Receptor alpha / biosynthesis. Mammary Neoplasms, Experimental / pathology. Receptors, Progesterone / biosynthesis
  • [MeSH-minor] Animals. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Cats. Female. Humans. Immunohistochemistry. Receptor, ErbB-2 / biosynthesis


64. Russo J, Balogh GA, Chen J, Fernandez SV, Fernbaugh R, Heulings R, Mailo DA, Moral R, Russo PA, Sheriff F, Vanegas JE, Wang R, Russo IH: The concept of stem cell in the mammary gland and its implication in morphogenesis, cancer and prevention. Front Biosci; 2006;11:151-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The concept of stem cell in the mammary gland and its implication in morphogenesis, cancer and prevention.
  • Despite the similarity in the lobular composition of the breast at menopause, the fact that nulliparous women are at higher risk of developing breast cancer than parous women, indicates that Lobules type 1 in these two groups of women might be biologically different, or exhibit different susceptibility to carcinogenesis.
  • Based on these observations it was postulated that the Lobule type 1 found in the breast of nulliparous women and of parous women with breast cancer never went through the process of differentiation, retaining a high concentration of epithelial cells that are targets for carcinogens and therefore susceptible to undergo neoplastic transformation, these cell are called Stem cells 1, whereas Lobules type 1 structures found in the breast of early parous postmenopausal women free of mammary pathology, on the other hand, are composed of an epithelial cell population that is refractory to transformation called Stem cells 2.
  • The identification of a putative breast stem cell (Stem cell 1) has reached in the last decade a significant impulse and several markers also reported for other tissues have been found in the mammary epithelial cells of both rodents and humans.
  • Although still more work needs to be done in order to better understand the role of the Stem cell 2 and its interaction with the genes that confer it a specific signature, collectively, the data presently available provides evidence that pregnancy, through the process of cell differentiation, shifts the Stem cell 1 to Stem cell 2, cells that exhibit a specific genomic signature that could be responsible for the refractoriness of the mammary gland to carcinogenesis.
  • [MeSH-major] Mammary Glands, Animal / pathology. Mammary Glands, Human / pathology. Neoplasms / metabolism. Stem Cells / metabolism
  • [MeSH-minor] Animals. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / pathology. Cell Differentiation. Cell Line, Tumor. Cell Transformation, Neoplastic. Epithelial Cells / metabolism. Estrogen Receptor alpha / biosynthesis. Estrogen Receptor beta / biosynthesis. Female. Gene Expression Regulation. Humans. Models, Biological. Pregnancy. RNA. Rats. Reverse Transcriptase Polymerase Chain Reaction. Time Factors

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146722.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA093599
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 63231-63-0 / RNA
  • [Number-of-references] 129
  •  go-up   go-down


65. Sorenmo KU, Kristiansen VM, Cofone MA, Shofer FS, Breen AM, Langeland M, Mongil CM, Grondahl AM, Teige J, Goldschmidt MH: Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet Comp Oncol; 2009 Sep;7(3):162-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence.
  • This study describes the clinical and histopathological findings in dogs with mammary gland tumours, and compares the histopathological and clinical evidence consistent with progression from benign to malignant to human breast cancer epidemiology.
  • These findings suggest that canine mammary tumours progress from benign to malignant; malignant tumours may be the end stage of a histological continuum with clinical and histopathological similarities to human breast carcinogenesis.
  • [MeSH-major] Dog Diseases / pathology. Mammary Neoplasms, Animal / pathology. Mixed Tumor, Malignant / veterinary. Neoplasms / veterinary
  • [MeSH-minor] Adenocarcinoma / veterinary. Adenoma / veterinary. Animals. Carcinoma / veterinary. Dogs. Female. Neoplasms, Complex and Mixed / pathology. Neoplasms, Complex and Mixed / veterinary. Neoplasms, Glandular and Epithelial / veterinary. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691645.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


66. Uehara N, Unami A, Kiyozuka Y, Shikata N, Oishi Y, Tsubura A: Parous mammary glands exhibit distinct alterations in gene expression and proliferation responsiveness to carcinogenic stimuli in Lewis rats. Oncol Rep; 2006 Apr;15(4):903-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parous mammary glands exhibit distinct alterations in gene expression and proliferation responsiveness to carcinogenic stimuli in Lewis rats.
  • Early full-term pregnancy affords lifetime protection against the development of breast cancer.
  • Parity-induced protection can be reproduced in a carcinogen-induced rat mammary carcinoma model, but the molecular mechanisms of this protection against carcinogenic stimuli in rat mammary glands have not been fully characterized.
  • To gain a better understanding of these molecular mechanisms, we used an oligonucleotide microarray to examine gene expression in parous and age-matched virgin (AMV) mammary glands of Lewis rats before and after carcinogen (N-methyl-N-nitrosourea;.
  • Parous mammary glands before MNU treatment showed up-regulation of multiple differentiation-related genes, such as whey acidic protein (Wap), casein beta (Csn2), casein gamma (Csng), lipopolysaccharide binding protein (Lbp), secreted phosphoprotein 1 (Spp1) and glycosylation-dependent cell adhesion molecule 1 (Glycam1).
  • Also, parous mammary glands before MNU treatment exhibited down-regulation of growth-related genes such as regenerating islet-derived 3 alpha (Reg3a), mesothelin (Msln), insulin-like growth factor 2 (Igf2) and insulin-like growth factor binding protein 4 (Igfbp4).
  • After MNU treatment, AMV mammary glands exhibited up-regulation of growth-related genes, such as Msln, cell division cycle 2 homolog A (Cdc2a), Igf2, Igfbp4, stathmin 1 (Stmn1) and homeobox, msh-like 1 (Msx1), whereas expression of these genes remained low in parous mammary glands.
  • AMV mammary glands also exhibited marked up-regulation of Cdc2a and Stmn1 in response to MNU.
  • After MNU treatment, the PCNA labeling index increased significantly in AMV mammary epithelial cells (13.7+/-1.1%), but remained low in parous mammary glands (3.6+/-0.4%).
  • The response of AMV mammary glands to carcinogenic stimuli includes up-regulation of growth-related genes and increased cell proliferation.
  • The lack of a similar response in parous mammary glands may explain parity-induced protection against mammary tumor development.
  • [MeSH-major] Cell Proliferation / drug effects. Gene Expression / drug effects. Mammary Glands, Animal / drug effects. Methylnitrosourea / toxicity

  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525678.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Proliferating Cell Nuclear Antigen; 684-93-5 / Methylnitrosourea
  •  go-up   go-down


67. Smith JM, Rao SS, Stump KC, Benazzi C, Sarli G, DeTolla LJ: Mammary ductal carcinoma with comedo pattern in a rhesus macaque. Contemp Top Lab Anim Sci; 2005 Jul;44(4):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary ductal carcinoma with comedo pattern in a rhesus macaque.
  • This animal was a retired breeder, currently in an aging study.
  • No exogenous hormone treatments were noted in the animal's history.
  • Differential diagnoses included sebaceous or mammary adenoma, carcinoma in situ, and lobular or ductular carcinoma.
  • Histopathology was consistent with a mammary ductal carcinoma with comedo pattern.
  • Further treatment was not performed and the animal remained clinically normal five years after the initial diagnosis.
  • Spontaneous mammary neoplasia is a major concern in human medicine, yet it rarely has been reported to occur in nonhuman primates.
  • This case is important in documenting an additional case of spontaneous mammary tumor development.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16050665.001).
  • [ISSN] 1060-0558
  • [Journal-full-title] Contemporary topics in laboratory animal science
  • [ISO-abbreviation] Contemp Top Lab Anim Sci
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Lawson JS, Tran DD, Carpenter E, Ford CE, Rawlinson WD, Whitaker NJ, Delprado W: Presence of mouse mammary tumour-like virus gene sequences may be associated with morphology of specific human breast cancer. J Clin Pathol; 2006 Dec;59(12):1287-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of mouse mammary tumour-like virus gene sequences may be associated with morphology of specific human breast cancer.
  • BACKGROUND: Mouse mammary tumour virus (MMTV) has a proven role in breast carcinogenesis in wild mice and genetically susceptible in-bred mice.
  • However, no evidence for a causal role of an MMTV-like virus in human breast cancer has emerged, although there are precedents for associations between specific histological characteristics of human cancers and the presence of oncogenic viruses.
  • AIM: To investigate the possibility of an association between breast cancer and MMTV-like viruses.
  • METHODS: Histological characteristics of invasive ductal human breast cancer specimens were compared with archival MMTV-associated mammary tumours from C3H experimental mice.
  • The presence of MMTV-like env DNA sequences in the human breast cancer specimens was determined by polymerase chain reaction and confirmed by Southern hybridisation.
  • RESULTS: MMTV-like env gene sequences were identified in 22 of 59 (37.3%) human breast cancer specimens.
  • Seventeen of 43 (39.5%) invasive ductal carcinoma breast cancer specimens and 4 of 16 (25%) ductal carcinoma in situ specimens had some histological characteristics, which were similar to MMTV-associated mouse mammary tumours.
  • A significant (p = 0.05) correlation was found between the grade of the human breast cancer and similarity to the mouse mammary tumours.
  • CONCLUSION: Some human breast cancer specimens, in which MMTV-like env DNA sequences have been identified, were shown to have histological characteristics (morphology) similar to MMTV-associated mouse mammary tumours.
  • [MeSH-major] Breast Neoplasms / virology. Carcinoma, Ductal, Breast / virology. Carcinoma, Intraductal, Noninfiltrating / virology. Mammary Tumor Virus, Mouse / isolation & purification
  • [MeSH-minor] Animals. DNA, Viral / analysis. Female. Humans. Mammary Neoplasms, Animal / pathology. Mammary Neoplasms, Animal / virology. Mice. Mice, Inbred C3H. Polymerase Chain Reaction / methods. Retroviridae Infections / complications. Tumor Virus Infections / complications. Viral Envelope Proteins / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1273-8 [10778951.001]
  • [Cites] Microsc Res Tech. 2005 Nov;68(3-4):209-21 [16276510.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2000 Dec 29;355(1404):1831-41 [11205344.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1754-9 [11245493.001]
  • [Cites] Breast Cancer Res. 2001;3(2):81-5 [11250750.001]
  • [Cites] Arch Virol. 2001;146(1):171-80 [11266212.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1118-20 [12631616.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):688-97 [15159298.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4105-11 [15205319.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4755-9 [15256443.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):721-6 [15305401.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6047-55 [15208658.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5647-9 [15355888.001]
  • [Cites] Adv Cancer Res. 1974;19(0):1-45 [4211879.001]
  • [Cites] Pathol Res Pract. 1980;166(4):515-35 [6253967.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Apr;78(4):2483-7 [6264479.001]
  • [Cites] Cancer Res. 1986 Apr;46(4 Pt 2):2096-100 [2418961.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5173-9 [7585568.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1999 Jan;4(1):105-22 [10219910.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7284-9 [15534103.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R1-11 [15642157.001]
  • [Cites] J Exp Med. 2005 Feb 7;201(3):431-9 [15684322.001]
  • [Cites] Dokl Biol Sci. 2004 Nov-Dec;399:423-6 [15717597.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6651-9 [16061645.001]
  • [CommentIn] J Clin Pathol. 2007 Sep;60(9):1071 [17158634.001]
  • (PMID = 16698952.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Viral Envelope Proteins
  • [Other-IDs] NLM/ PMC1860546
  •  go-up   go-down


69. Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, Kappes JC, Barnes S, Kimberly RP, Grizzle WE, Zhang HG: Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol; 2006 Feb 1;176(3):1375-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function.
  • In this study, we show that pretreatment of mice with exosomes produced by TS/A or 4T.1 murine mammary tumor cells resulted in accelerated growth of implanted tumor cells in both syngeneic BALB/c mice and nude mice.
  • The presentation of tumor Ags by exosomes is under consideration as a cancer vaccine strategy; however, we found that pretreatment of mice with tumor exosomes blunted the protective effect of syngeneic dendritic cells pulsed ex vivo with tumor exosomes.
  • [MeSH-major] Carcinoma / immunology. Cell Proliferation. Cytoplasmic Vesicles / immunology. Cytotoxicity, Immunologic / immunology. Exocytosis / immunology. Immunosuppression. Killer Cells, Natural / immunology. Mammary Neoplasms, Animal / immunology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424164.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA107181; United States / NCI NIH HHS / CA / R01-CA116092
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Bullitt E, Wolthusen PA, Brubaker L, Lin W, Zeng D, Van Dyke T: Malignancy-associated vessel tortuosity: a computer-assisted, MR angiographic study of choroid plexus carcinoma in genetically engineered mice. AJNR Am J Neuroradiol; 2006 Mar;27(3):612-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancy-associated vessel tortuosity: a computer-assisted, MR angiographic study of choroid plexus carcinoma in genetically engineered mice.
  • BACKGROUND AND PURPOSE: The ability to assess tumor malignancy and monitor treatment response noninvasively would be of value to both clinicians and animal investigators.
  • This report describes the MR imaging characteristics of a genetically engineered mouse model of choroid plexus carcinoma (CPC) during tumor growth and progression to malignancy.
  • METHODS: MR images of 9 healthy mice and of 20 CPC mice with precancerous choroid dysplasia or with cancer over a wide range of sizes were analyzed.
  • CONCLUSION: To the best of our knowledge, this report provides the first description of in vivo, MR imaging characteristics of genetically engineered CPC mice during the progression from dysplasia to cancer.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1994 Aug 26;78(4):703-11 [8069917.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1969 Apr;105(4):795-805 [4308528.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):585-90 [15560716.001]
  • [Cites] Med Image Anal. 2005 Feb;9(1):39-49 [15581811.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8218-23 [16166297.001]
  • [Cites] Acad Radiol. 2005 Oct;12(10):1232-40 [16179200.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):94-5 [10639502.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Feb;14(1):31-6 [10850285.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Neuroradiology. 2001 May;43(5):345-52 [11396737.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):6017-30 [11486039.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2186-9 [11691952.001]
  • [Cites] Cell. 2002 Jan 25;108(2):135-44 [11832204.001]
  • [Cites] Int J Mol Med. 2002 Mar;9(3):299-310 [11836637.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Feb;21(2):61-75 [11929106.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1284-91 [11948144.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):783-9 [12185064.001]
  • [Cites] J Neuroradiol. 2002 Jun;29(2):105-13 [12297732.001]
  • [Cites] Neuroradiology. 2003 Apr;45(4):205-11 [12687302.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71 [12956271.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):421-37 [14973386.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):577-84 [15560715.001]
  • (PMID = 16552004.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NIBIB NIH HHS / EB / R01 EB000219-08A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS53783; NLM/ PMC2504702
  •  go-up   go-down


71. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB: Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci U S A; 2005 Sep 27;102(39):14034-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice.
  • Limitations of current viral-based gene therapies for malignant tumors include lack of cancer-specific targeting and insufficient tumor delivery.
  • To ameliorate these problems and develop a truly effective adenovirus gene-based therapy for cancer, we constructed a conditionally replication competent adenovirus (CRCA) manifesting the unique properties of tumor-specific virus replication in combination with production of a cancer-selective cytotoxic cytokine, melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), which embodies potent bystander antitumor activity.
  • Cancer cell selective tropism was ensured by engineering the expression of the adenoviral E1A protein, necessary for viral replication, under the control of a minimal promoter region of progression elevated gene-3 (PEG-3), which functions selectively in diverse cancer cells with minimal activity in normal cells.
  • Infection of this CRCA (designated Ad.PEG-E1A-mda-7) in normal mammary epithelial cells and breast cancer cells confirmed cancer cell selective adenoviral replication, mda-7/IL-24 expression, growth inhibition, and apoptosis induction.
  • Injecting Ad.PEG-E1A-mda-7 into human breast cancer xenografts in athymic nude mice completely eradicated not only the primary tumor but also distant tumors (established on the opposite flank of the animal) thereby implementing a cure.
  • This dual cancer-specific targeting strategy provides an effective approach for treating breast and other human neoplasms with the potential for eradicating both primary tumors and metastatic disease.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 Oct 25;20(48):7051-63 [11704829.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2247-55 [15674324.001]
  • [Cites] Oncogene. 2002 Jan 24;21(5):708-18 [11850799.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):130-41 [11905804.001]
  • [Cites] J Immunol. 2002 Jun 15;168(12):6041-6 [12055212.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4558-66 [12085234.001]
  • [Cites] Cancer Cell. 2002 May;1(4):325-37 [12086848.001]
  • [Cites] Curr Gene Ther. 2001 May;1(1):101-22 [12109134.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10054-9 [12114539.001]
  • [Cites] Hum Gene Ther. 2002 Sep 20;13(14):1737-50 [12396626.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):850-61 [12415255.001]
  • [Cites] J Cell Physiol. 2003 Aug;196(2):334-45 [12811827.001]
  • [Cites] Methods Mol Biol. 2003;234:1-16 [12824521.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jun;79(3):287-99 [12846413.001]
  • [Cites] Curr Gene Ther. 2003 Aug;3(4):357-85 [12871022.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5105-13 [12941841.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S23-37 [14508078.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S64-70 [14508082.001]
  • [Cites] Curr Opin Mol Ther. 2003 Oct;5(5):475-82 [14601515.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8138-44 [14678967.001]
  • [Cites] Annu Rev Immunol. 2004;22:929-79 [15032600.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):2988-93 [15126330.001]
  • [Cites] Expert Opin Biol Ther. 2004 May;4(5):683-96 [15155160.001]
  • [Cites] Eur J Pharmacol. 2004 Sep 13;498(1-3):1-8 [15363969.001]
  • [Cites] Oncogene. 2004 Oct 7;23(46):7679-90 [15334067.001]
  • [Cites] Oncogene. 1995 Dec 21;11(12):2477-86 [8545104.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9160-5 [8799171.001]
  • [Cites] Science. 1996 Oct 18;274(5286):373-6 [8832876.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9125-30 [9256446.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15115-20 [10611347.001]
  • [Cites] Adv Exp Med Biol. 2000;465:239-61 [10810631.001]
  • [Cites] Oncogene. 2000 Jul 13;19(30):3411-21 [10918598.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jul;62(1):51-62 [10989985.001]
  • [Cites] Hum Gene Ther. 2000 Sep 20;11(14):2009-24 [11020800.001]
  • [Cites] Biotechniques. 2001 Mar;30(3):612-6, 618-9 [11252797.001]
  • [Cites] Nucleic Acids Res. 2001 Apr 15;29(8):1661-71 [11292838.001]
  • [Cites] Oncogene. 2001 May 31;20(25):3266-80 [11423976.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1062-74 [11459867.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10332-7 [11526239.001]
  • [Cites] Biochem Mol Med. 1997 Aug;61(2):127-35 [9259977.001]
  • [Cites] N Engl J Med. 1998 Oct 1;339(14):974-84 [9753714.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14400-5 [9826712.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7199-206 [15534093.001]
  • [Cites] Mol Ther. 2005 Jan;11(1):4-18 [15585401.001]
  • [Cites] Mol Ther. 2005 Jan;11(1):149-59 [15585416.001]
  • [Cites] Mol Ther. 2005 Jan;11(1):160-72 [15585417.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1059-64 [15647352.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):367-74 [15067541.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Dec 17;53(2):135-54 [11731024.001]
  • (PMID = 16172403.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA035675; United States / NCI NIH HHS / CA / R01 CA098712; United States / NCI NIH HHS / CA / CA097318; United States / NCI NIH HHS / CA / R01 CA035675; United States / NCI NIH HHS / CA / R01 CA097318; United States / NCI NIH HHS / CA / P01 CA104177; United States / NCI NIH HHS / CA / CA098712
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / Interleukins; 0 / interleukin-24
  • [Other-IDs] NLM/ PMC1236587
  •  go-up   go-down


72. Rodriguez-Collazo P, Snyder SK, Chiffer RC, Zlatanova J, Leuba SH, Smith CL: cAMP signaling induces rapid loss of histone H3 phosphorylation in mammary adenocarcinoma-derived cell lines. Exp Cell Res; 2008 Jan 1;314(1):1-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] cAMP signaling induces rapid loss of histone H3 phosphorylation in mammary adenocarcinoma-derived cell lines.
  • Similar effects of cAMP signaling on H3 phosphorylation are observed in a variety of mammary adenocarcinoma-derived cell lines.
  • In syngeneic human breast-derived cell lines, one diploid and non-transformed, the other derived from a ductal carcinoma, the loss of H3 phosphorylation is significantly more sensitive to cAMP concentration in the transformed cell line.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950276.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA122177-01A1; United States / Intramural NIH HHS / / Z01 BC010289-10; United States / NCI NIH HHS / CA / 1K011CA122177-01A1; United States / NCI NIH HHS / CA / K01 CA122177-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 1F7A44V6OU / Colforsin; 23583-48-4 / 8-Bromo Cyclic Adenosine Monophosphate; E0399OZS9N / Cyclic AMP
  • [Other-IDs] NLM/ NIHMS35991; NLM/ PMC4426871
  •  go-up   go-down


73. Zhao L, Zhan Y, Rutkowski JL, Feuerstein GZ, Wang X: Correlation between 2- and 3-dimensional assessment of tumor volume and vascular density by ultrasonography in a transgenic mouse model of mammary carcinoma. J Ultrasound Med; 2010 Apr;29(4):587-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between 2- and 3-dimensional assessment of tumor volume and vascular density by ultrasonography in a transgenic mouse model of mammary carcinoma.
  • We hereby investigated the 2D and 3D sonographic correlation for tumor volume and vascular density confirmed by histologic assessment in the polyoma virus middle T antigen (PyMT) mouse model of mammary carcinoma.
  • [MeSH-major] Mammary Neoplasms, Animal / ultrasonography. Neovascularization, Pathologic / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375377.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Xanthenes; 82354-19-6 / Texas red
  •  go-up   go-down


74. Tsubura A, Yoshizawa K, Uehara N, Yuri T, Matsuoka Y: Multistep mouse mammary tumorigenesis through pre-neoplasia to neoplasia and acquisition of metastatic potential. Med Mol Morphol; 2007 Mar;40(1):9-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multistep mouse mammary tumorigenesis through pre-neoplasia to neoplasia and acquisition of metastatic potential.
  • Human breast tissue can give rise to hyperplasias, atypical hyperplasias, and in situ carcinomas originating in a terminal duct-lobular unit (TDLU).
  • These entities are associated with increased risk of subsequent development of invasive carcinoma.
  • Human breast carcinomas arise via intermediate steps known as precursor or premalignant lesions.
  • However, it is difficult to perform stepwise observation of the progression of human breast cancer.
  • Mouse mammary tissue can give rise to several characteristic types of premalignant hyperplasia and tumor, originating in a duct or acinus, that progress to carcinoma.
  • Three specific types of mouse mammary lesion with premalignant potential have been identified: hyperplastic alveolar nodule (HAN), plaque (PLQ), and ductal hyperplasia (DH).
  • Some invasive breast carcinomas acquire metastatic potential and may cause the death of the patient.
  • Mouse mammary carcinomas rarely metastasize, but there exist mouse models of metastasis of mammary carcinoma.
  • [MeSH-major] Mammary Neoplasms, Animal / pathology. Neoplasm Metastasis / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma / secondary. Animals. Disease Models, Animal. Female. Mammary Glands, Animal / pathology. Mammary Neoplasms, Experimental / etiology. Mammary Neoplasms, Experimental / pathology. Mice

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1979 May;62(5):1287-93 [286104.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):421-37 [14973386.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):2151-9 [11106587.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5291-8 [1394133.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(2):101-13 [16319986.001]
  • [Cites] Int J Mol Med. 1998 Oct;2(4):437-44 [9857231.001]
  • [Cites] Gan. 1981 Oct;72(5):639-46 [7327365.001]
  • [Cites] J Natl Cancer Inst. 1960 Apr;24:953-69 [13821714.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2085-91 [9395206.001]
  • [Cites] Eur J Cancer. 1965 Jun;1(1):41-50 [5896138.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;415(6):533-8 [2477946.001]
  • [Cites] J Natl Cancer Inst. 1979 Feb;62(2):397-405 [105203.001]
  • [Cites] IARC Sci Publ. 1990;(99):47-78 [2093658.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 2;1603(1):1-9 [12242106.001]
  • [Cites] Histol Histopathol. 1995 Oct;10(4):1047-55 [8573996.001]
  • [Cites] Biochim Biophys Acta. 1974 Dec 31;355(3-4):236-59 [4142395.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1999 Jan;4(1):105-22 [10219910.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):663-7 [7678778.001]
  • [Cites] Acta Anat (Basel). 1991;140(3):287-93 [1714223.001]
  • [Cites] J Natl Cancer Inst. 1971 Apr;46(4):885-97 [5573773.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] Cancer Detect Prev. 1998;22(4):313-8 [9674874.001]
  • [Cites] Fed Proc. 1975 Jan;34(1):64-7 [162797.001]
  • [Cites] Cancer Res. 1988 Nov 15;48(22):6555-9 [2846153.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Jul;8(3):321-34 [14973376.001]
  • [Cites] J Natl Cancer Inst. 1964 Jan;32:237-51 [14114970.001]
  • [Cites] Cancer Lett. 1996 Aug 23;106(1):83-9 [8827050.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):393-407 [14973384.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):968-88 [10713680.001]
  • [Cites] Toxicol Pathol. 2001 Jan-Feb;29(1):105-16 [11215674.001]
  • [Cites] Int Rev Cytol. 1986;103:303-40 [3017886.001]
  • [Cites] J Natl Cancer Inst. 1974 Jun;52(6):1855-63 [4834412.001]
  • [Cites] Cell Prolif. 1996 Nov;29(11):623-39 [9105418.001]
  • [Cites] J Virol. 1990 Apr;64(4):1794-802 [2157060.001]
  • [Cites] Carcinogenesis. 1995 Oct;16(10):2507-13 [7586159.001]
  • [Cites] Med Mol Morphol. 2006 Mar;39(1):8-13 [16575508.001]
  • [Cites] FASEB J. 2002 Jun;16(8):881-3 [11967232.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2589-95 [179706.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):698-702 [1846961.001]
  • [Cites] J Natl Cancer Inst. 1976 Sep;57(3):519-26 [978764.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1052-8 [10713689.001]
  • [Cites] Breast Cancer Res Treat. 1991 Jan-Feb;17(3):239-43 [1710155.001]
  • [Cites] Oncogene. 1996 Dec 19;13(12):2507-15 [9000125.001]
  • [Cites] Anticancer Res. 1991 Sep-Oct;11(5):1719-23 [1768042.001]
  • [Cites] Oncogene. 1992 May;7(5):1027-32 [1349163.001]
  • (PMID = 17384984.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 51
  •  go-up   go-down


75. Madrazo J, García-Fernández RA, García-Iglesias MJ, Durán AJ, Espinosa J, Pérez-Martínez C: The role of CD44 adhesion factor in canine mammary carcinomas. Vet J; 2009 Jun;180(3):371-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of CD44 adhesion factor in canine mammary carcinomas.
  • CD44 is an adhesion molecule implicated in the progression of human breast cancer.
  • The purpose of this study was to describe CD44 antigen expression in canine mammary carcinomas and to evaluate its prognostic significance in relation to other clinico-pathological variables.
  • Complex (grade I) and anaplastic (grade III) carcinomas exhibited more intense expression of this antigen than did some tubulopapillary and most solid carcinomas (grade II).
  • Although reduced CD44 expression was associated with infiltrative growth and vascular invasion in solid carcinomas, intense expression was also observed in anaplastic tumours.
  • Although overall these findings suggest a role for this adhesion factor in canine mammary tumour development and progression, the complexity and apparently paradoxical nature of some of the findings currently limit the use of this immunohistochemical marker as a prognostic indicator.
  • [MeSH-major] Antigens, CD44 / metabolism. Carcinoma / veterinary. Dog Diseases / metabolism. Mammary Neoplasms, Animal / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299241.001).
  • [ISSN] 1090-0233
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44
  •  go-up   go-down


76. Lebret SC, Newgreen DF, Waltham MC, Price JT, Thompson EW, Ackland ML: Myoepithelial molecular markers in human breast carcinoma PMC42-LA cells are induced by extracellular matrix and stromal cells. In Vitro Cell Dev Biol Anim; 2006 Nov-Dec;42(10):298-307
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoepithelial molecular markers in human breast carcinoma PMC42-LA cells are induced by extracellular matrix and stromal cells.
  • To investigate how lineage development is regulated by 3-D culture and microenvironment components, we used the PMC42-LA human breast carcinoma cell line, which possesses stem cell characteristics.
  • When cultured on a two-dimensional glass substrate, PMC42-LA cells formed a monolayer and expressed predominantly luminal epithelial markers, including cytokeratins 8, 18, and 19; E-cadherin; and sialomucin.
  • When cultured within Engelbreth-Holm- Swarm sarcoma-derived basement membrane matrix (EHS matrix), PMC42-LA cells formed organoids in which the expression of luminal markers was reduced and the expression of other myoepithelial-specific markers (cytokeratin 17 and P-cadherin) was promoted.
  • The presence of primary human mammary gland fibroblasts within the EHS matrix induced expression of the key myoepithelial-specific markers, alpha-smooth muscle actin and cytokeratin 14.
  • Conditioned medium from the mammary fibroblasts was equally effective in inducing myoepithelial marker expression.
  • [MeSH-minor] Biomarkers / metabolism. Cell Line, Transformed. Cell Line, Tumor. Culture Media, Conditioned. Fibroblasts / cytology. Fibroblasts / metabolism. Humans. Keratin-8 / metabolism. Mammary Glands, Human / cytology. Mammary Glands, Human / pathology. Phenotype. Protein Transport

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Anat (Basel). 1995;154(1):8-20 [8714286.001]
  • [Cites] J Cell Sci. 1999 Apr;112 ( Pt 7):1035-44 [10198285.001]
  • [Cites] Am J Pathol. 1986 Aug;124(2):199-206 [3740213.001]
  • [Cites] J Cell Biol. 1994 May;125(3):681-93 [8175886.001]
  • [Cites] Exp Mol Pathol. 2003 Apr;74(2):113-22 [12710942.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Mol Biol Cell. 1995 Oct;6(10):1287-303 [8573787.001]
  • [Cites] Breast Cancer Res. 2001;3(4):230-7 [11434874.001]
  • [Cites] Int J Cancer. 1988 Aug 15;42(2):147-53 [2456993.001]
  • [Cites] J Natl Cancer Inst. 1983 Apr;70(4):649-61 [6572752.001]
  • [Cites] Breast Cancer Res. 2001;3(1):1-4 [11250738.001]
  • [Cites] Dev Biol. 2002 May 1;245(1):42-56 [11969254.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):737-46 [12065684.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:155-63 [15153430.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):1949-58 [9815584.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):999-1003 [8430113.001]
  • [Cites] J Cell Sci. 1989 Jul;93 ( Pt 3):419-26 [2481679.001]
  • [Cites] J Natl Cancer Inst. 1984 Sep;73(3):643-8 [6381852.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(1):21-31 [8738603.001]
  • [Cites] Int J Cancer. 1981 Jul 15;28(1):17-21 [7309278.001]
  • [Cites] Lab Invest. 2003 Mar;83(3):435-48 [12649344.001]
  • [Cites] J Histochem Cytochem. 1989 Jul;37(7):1087-100 [2471725.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1254-60 [10728684.001]
  • [Cites] Exp Cell Res. 2001 Feb 1;263(1):14-22 [11161701.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] J Cell Sci. 1989 Nov;94 ( Pt 3):403-13 [2483723.001]
  • [Cites] J Cell Biol. 1999 Nov 1;147(3):631-44 [10545506.001]
  • [Cites] Breast Cancer Res. 2002;4(6):224-30 [12473168.001]
  • [Cites] Pathol Annu. 1971;6:1-59 [4342307.001]
  • [Cites] Dev Biol. 1999 Feb 1;206(1):88-99 [9918697.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(2):93-109 [11519870.001]
  • [Cites] Dev Biol. 1995 Jun;169(2):511-9 [7781895.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Int J Cancer. 1980 Nov 15;26(5):577-84 [6263809.001]
  • [Cites] J Natl Cancer Inst. 1983 Dec;71(6):1193-203 [6606728.001]
  • [Cites] Breast Cancer Res. 2003;5(3):130-5 [12793893.001]
  • [Cites] Curr Opin Cell Biol. 1999 Oct;11(5):554-60 [10508659.001]
  • [Cites] Genes Dev. 2003 May 15;17 (10 ):1253-70 [12756227.001]
  • [Cites] Differentiation. 1998 Aug;63(4):201-13 [9745711.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1999 Jan;4(1):9-19 [10219903.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • (PMID = 17316063.001).
  • [ISSN] 1071-2690
  • [Journal-full-title] In vitro cellular & developmental biology. Animal
  • [ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Culture Media, Conditioned; 0 / Keratin-8
  •  go-up   go-down


77. Tarara RP: Review of mammary gland neoplasia in nonhuman primates. Breast Dis; 2007;28:23-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of mammary gland neoplasia in nonhuman primates.
  • [MeSH-major] Mammary Neoplasms, Animal / pathology
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Female. Hyperplasia / pathology. Macaca

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057540.001).
  • [ISSN] 0888-6008
  • [Journal-full-title] Breast disease
  • [ISO-abbreviation] Breast Dis
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P51 RR000169
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 31
  •  go-up   go-down


78. Crowley MR, Frost A, Chen DT, Baffi MO, Nicola T, Serra R: Transforming growth factor-beta signaling helps specify tumor type in DMBA and hormone-induced mammary cancers. Differentiation; 2006 Feb;74(1):40-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor-beta signaling helps specify tumor type in DMBA and hormone-induced mammary cancers.
  • To determine the role of transforming growth factor-beta (TGF-beta) signaling in mammary development and tumor formation, we previously generated transgenic mice that expressed a dominant-negative form of the TGF-beta type II receptor (DNIIR) under the control of DNA regulatory elements from the metallothionein promoter (MT-DNIIR-28).
  • In this report, we tested the hypothesis that loss of TGF-beta signaling in the mammary gland alters the development of chemically or hormonally induced tumors in mice.
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Carcinogens / toxicity. Mammary Neoplasms, Animal / etiology. Pituitary Hormones / toxicity. Signal Transduction. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Female. Genes, Dominant. Mice. Mice, Transgenic. Myoepithelioma / etiology. Myoepithelioma / pathology. Protein-Serine-Threonine Kinases. Receptors, Transforming Growth Factor beta / genetics. Receptors, Transforming Growth Factor beta / physiology

  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466399.001).
  • [ISSN] 0301-4681
  • [Journal-full-title] Differentiation; research in biological diversity
  • [ISO-abbreviation] Differentiation
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA91974
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Pituitary Hormones; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


79. Rai A, Rajeshkumar NV, Gulati A: Effect of the ET(B) receptor agonist, IRL-1620, on paclitaxel plasma pharmacokinetics of breast tumor rats. Exp Biol Med (Maywood); 2006 Jun;231(6):1120-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endothelin (ET)-B receptors are expressed in human breast carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacokinetics. Endothelins / pharmacology. Mammary Neoplasms, Animal / drug therapy. Paclitaxel / pharmacokinetics. Peptide Fragments / pharmacology. Receptor, Endothelin B / agonists

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741060.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Endothelins; 0 / Peptide Fragments; 0 / Receptor, Endothelin B; 142569-99-1 / IRL 1620; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


80. Pinho SS, Matos AJ, Lopes C, Marcos NT, Carvalheira J, Reis CA, Gärtner F: Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression. BMC Cancer; 2007;7:124
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression.
  • BACKGROUND: Sialyl Lewis x (sLex) antigen is a carbohydrate antigen that is considered not only a marker for cancer but also implicated functionally in the malignant behaviour of cancer cells.
  • Overexpression of sLex is associated with enhanced progression and metastases of many types of cancer including those of the mammary gland.
  • Canine mammary tumours can invade and give rise to metastases via either lymphatic or blood vessels.E-Cadherin is specifically involved in epithelial cell-to-cell adhesion.
  • In cancer, E-Cadherin underexpression is one of the alterations that characterizes the invasive phenotype and is considered an invasion/tumour suppressor gene.
  • Partial or complete loss of E-Cadherin expression correlates with poor prognosis in canine malignant mammary cancer.
  • The aim of this study was to analyse the sLex expression in canine malignant mammary tumours and to evaluate if the presence of sLex correlates with the expression of E-Cadherin and with clinicopathological features.
  • METHODS: Fifty-three cases of canine mammary carcinomas were analysed immunohistochemically using monoclonal antibodies against sLex (IgM) and E-Cadherin (IgG).
  • RESULTS: sLex expression was consistently demonstrated in all cases of canine mammary carcinomas with different levels of expression.
  • CONCLUSION: In the present study we demonstrate the importance of sLex in the malignant phenotype of canine malignant mammary tumours.
  • Our results support the use of sLex as a prognostic tumour marker in canine mammary carcinomas.
  • Future studies are warranted to clarify the molecular mechanism underlying the relation between sLex and E-Cadherin in canine mammary carcinoma cells which represents an important comparative model to woman breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cadherins / metabolism. Mammary Neoplasms, Animal / metabolism. Mammary Neoplasms, Animal / pathology. Neoplasm Invasiveness / pathology. Oligosaccharides / metabolism
  • [MeSH-minor] Animals. Biopsy, Needle. Cell Transformation, Neoplastic / pathology. Dogs. Female. Gene Expression Regulation, Neoplastic. Immunohistochemistry. Models, Animal. Neoplasm Staging. Probability. Random Allocation. Reference Values. Sensitivity and Specificity

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Dec;83(12):1681-7 [11104566.001]
  • [Cites] Int J Cancer. 2000 Oct 15;88(2):281-6 [11004681.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):673-85 [11857299.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 May;128(5):257-64 [12029441.001]
  • [Cites] Oncogene. 2002 May 16;21(22):3631-43 [12032865.001]
  • [Cites] Hum Gene Ther. 2002 Jul 1;13(10):1245-58 [12133277.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):619-28 [12163386.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] Acta Biochim Pol. 2002;49(2):303-11 [12362971.001]
  • [Cites] J Vet Med Sci. 2002 Oct;64(10):949-52 [12419875.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(2):141-8 [12725414.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 2003 May;33(3):573-96 [12852237.001]
  • [Cites] Glycoconj J. 2004;20(1):71-8 [14993838.001]
  • [Cites] Cancer Sci. 2004 May;95(5):377-84 [15132763.001]
  • [Cites] J Vet Med A Physiol Pathol Clin Med. 2003 Dec;50(10):496-500 [15157016.001]
  • [Cites] Arch Biochem Biophys. 2004 Jun 15;426(2):122-31 [15158662.001]
  • [Cites] Glycoconj J. 2004;20(5):353-64 [15229399.001]
  • [Cites] Eur J Cancer. 1975 Jun;11(6):389-96 [1164917.001]
  • [Cites] Invest Cell Pathol. 1979 Oct-Dec;2(4):257-75 [396282.001]
  • [Cites] Am J Clin Pathol. 1981 May;75(5):734-8 [6165237.001]
  • [Cites] J Biol Chem. 1984 Aug 25;259(16):10511-7 [6469974.001]
  • [Cites] Semin Vet Med Surg (Small Anim). 1986 Feb;1(1):25-32 [3507784.001]
  • [Cites] Cancer Invest. 1991;9(5):543-51 [1933487.001]
  • [Cites] J Clin Pathol. 1992 Jun;45(6):517-20 [1624599.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1929-35 [8410120.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):1425-31 [7507108.001]
  • [Cites] Biochim Biophys Acta. 1994 May 27;1198(1):11-26 [8199193.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7390-7 [7519775.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1817-9 [7728744.001]
  • [Cites] Oncology. 1995 Jul-Aug;52(4):272-7 [7777238.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2237-44 [8625291.001]
  • [Cites] J Pathol. 1996 Aug;179(4):358-69 [8869281.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5309-18 [8968075.001]
  • [Cites] Jpn J Clin Oncol. 1997 Jun;27(3):135-9 [9255266.001]
  • [Cites] World J Surg. 1997 Sep;21(7):773-6 [9276710.001]
  • [Cites] Glycoconj J. 1997 Aug;14(5):577-84 [9298690.001]
  • [Cites] Gastroenterology. 1998 Mar;114(3):462-70 [9496936.001]
  • [Cites] Head Neck. 1998 Dec;20(8):726-31 [9790295.001]
  • [Cites] Head Neck. 1999 Jul;21(4):330-7 [10376753.001]
  • [Cites] Vet Pathol. 1999 Sep;36(5):423-36 [10490210.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):59-67 [15603855.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jun;4(6):477-88 [15931257.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1615-22 [16033070.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):398-408 [15906360.001]
  • [Cites] Res Vet Sci. 2006 Jun;80(3):317-23 [16181651.001]
  • [Cites] J Comp Pathol. 2006 Feb-Apr;134(2-3):182-9 [16545841.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2193-8 [11854515.001]
  • (PMID = 17617904.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Oligosaccharides
  • [Other-IDs] NLM/ PMC1933546
  •  go-up   go-down


81. Wegwitz F, Kluth MA, Mänz C, Otto B, Gruner K, Heinlein C, Kühl M, Warnecke G, Schumacher U, Deppert W, Tolstonog GV: Tumorigenic WAP-T mouse mammary carcinoma cells: a model for a self-reproducing homeostatic cancer cell system. PLoS One; 2010;5(8):e12103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumorigenic WAP-T mouse mammary carcinoma cells: a model for a self-reproducing homeostatic cancer cell system.
  • BACKGROUND: In analogy to normal stem cell differentiation, the current cancer stem cell (CSC) model presumes a hierarchical organization and an irreversible differentiation in tumor tissue.
  • METHODOLOGY/PRINCIPAL FINDINGS: In this study we analyzed the CSC properties of mammary carcinoma cells derived from transgenic (WAP-T) mice.
  • CONCLUSIONS/SIGNIFICANCE: G-2 cells constitute a self-reproducing cancer cell system, maintained by bi- and unidirectional conversion of complementary cellular subsets.
  • [MeSH-major] Homeostasis. Mammary Neoplasms, Animal / pathology. Models, Biological

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2006 Mar;133(5):823-32 [16439476.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] Dev Biol. 2006 May 15;293(2):565-80 [16581056.001]
  • [Cites] Science. 2006 Oct 13;314(5797):298-300 [17038622.001]
  • [Cites] Stem Cell Rev. 2005;1(3):215-23 [17142858.001]
  • [Cites] Oncogene. 2006 Dec 14;25(59):7663-72 [16847453.001]
  • [Cites] J Cell Biol. 2007 Jan 1;176(1):19-26 [17190790.001]
  • [Cites] Adv Cancer Res. 2007;98:117-47 [17433909.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8671-81 [17875707.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:675-99 [17645413.001]
  • [Cites] J Cell Sci. 2008 Oct 15;121(Pt 20):3393-402 [18827017.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Neoplasia. 2008 Dec;10(12):1433-43 [19048122.001]
  • [Cites] Carcinogenesis. 2008 Dec;29(12):2377-84 [18701433.001]
  • [Cites] Carcinogenesis. 2008 Dec;29(12):2267-78 [18791199.001]
  • [Cites] Annu Rev Pathol. 2007;2:175-89 [18039097.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):542-58 [18068631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1680-5 [18230721.001]
  • [Cites] Stem Cells. 2008 Feb;26(2):364-71 [17975224.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1701-9 [18092324.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):295-305 [18297062.001]
  • [Cites] Int J Biol Sci. 2008;4(3):133-42 [18461147.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):79-89 [18598946.001]
  • [Cites] PLoS One. 2008;3(8):e2888 [18682804.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14076-81 [18780791.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7711-7 [18829523.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Blood. 2008 Dec 15;112(13):4793-807 [19064739.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):35-44 [19111879.001]
  • [Cites] Breast Cancer Res. 2008;10(5):R75 [18782450.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):663-71 [19147582.001]
  • [Cites] BMC Genomics. 2008;9:591 [19063729.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):265-73 [19262571.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2887-95 [19276366.001]
  • [Cites] Bioessays. 2009 May;31(5):546-60 [19319911.001]
  • [Cites] Am J Pathol. 2009 May;174(5):1588-93 [19342369.001]
  • [Cites] Dev Dyn. 2004 Jun;230(2):350-60 [15162513.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] Nature. 2008 May 22;453(7194):544-7 [18497826.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4674-82 [18559513.001]
  • [Cites] Dev Biol. 2009 May 15;329(2):227-41 [19269284.001]
  • [Cites] Int J Cancer. 2009 Jul 1;125(1):62-70 [19384954.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1429-37 [19487819.001]
  • [Cites] Genes Dev. 2009 Jun 15;23(12):1450-60 [19528321.001]
  • [Cites] Cell. 2009 Jul 10;138(1):129-45 [19596240.001]
  • [Cites] PLoS One. 2009;4(7):e6381 [19636430.001]
  • [Cites] Nat Med. 2009 Sep;15(9):1010-2 [19734877.001]
  • [Cites] Cell. 2009 Sep 4;138(5):822-9 [19737509.001]
  • [Cites] Nat Cell Biol. 2009 Nov;11(11):1297-304 [19801974.001]
  • [Cites] Cell. 2009 Nov 13;139(4):693-706 [19878981.001]
  • [Cites] Genes Dev. 2009 Nov 15;23(22):2563-77 [19933147.001]
  • [Cites] Cell. 2009 Nov 25;139(5):871-90 [19945376.001]
  • [Cites] Histochem Cell Biol. 2010 Feb;133(2):213-21 [19937336.001]
  • [Cites] J Biol. 2009;8(8):70 [19769787.001]
  • [Cites] Breast Cancer Res. 2009;11(6):R82 [19906290.001]
  • [Cites] Cancer Sci. 2009 Dec;100(12):2275-82 [19737148.001]
  • [Cites] Cancer Res. 2010 Apr 15;70(8):3005-8 [20395197.001]
  • [Cites] Cell Stem Cell. 2010 Jul 2;7(1):127-33 [20621056.001]
  • [Cites] J Cell Sci. 1999 Dec;112 ( Pt 24):4615-25 [10574710.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1028-37 [10713686.001]
  • [Cites] Mol Med. 1998 Jun;4(6):392-401 [10780882.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3024-34 [12789277.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11281-92 [14662758.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Cancer Res. 1978 Oct;38(10):3174-81 [210930.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Dec;75(12):6093-7 [366610.001]
  • [Cites] J Natl Cancer Inst. 1982 May;68(5):799-811 [6121926.001]
  • [Cites] Cancer Res. 1986 May;46(5):2203-7 [3516380.001]
  • [Cites] Oncogene. 1993 Jul;8(7):1965-71 [8390039.001]
  • [Cites] Development. 1995 Jul;121(7):2079-90 [7635053.001]
  • [Cites] Oncogene. 1998 Apr 23;16(16):2103-14 [9572491.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Oct;34(9):711-21 [9794223.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):37-47 [15886885.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):49-59 [15886886.001]
  • [Cites] Stem Cells. 2005 Jun-Jul;23(6):719-26 [15917468.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4645-59 [15870706.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5991-5; discussion 5995 [16024595.001]
  • [Cites] BMC Bioinformatics. 2005;6:232 [16176576.001]
  • (PMID = 20730114.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2920333
  •  go-up   go-down


82. Manuali E, Eleni C, Giovannini P, Costarelli S, Ciorba A: Unusual finding in a nipple discharge of a female dog: dirofilariasis of the breast. Diagn Cytopathol; 2005 Feb;32(2):108-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The case describes an unusual finding of dirofilariasis presenting as a breast lump, simulating an inflammatory breast carcinoma.
  • [MeSH-major] Dirofilaria. Dirofilariasis / pathology. Dog Diseases / pathology. Mammary Glands, Animal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15637669.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Martinez-Orozco R, Navarro-Tito N, Soto-Guzman A, Castro-Sanchez L, Perez Salazar E: Arachidonic acid promotes epithelial-to-mesenchymal-like transition in mammary epithelial cells MCF10A. Eur J Cell Biol; 2010 Jun;89(6):476-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arachidonic acid promotes epithelial-to-mesenchymal-like transition in mammary epithelial cells MCF10A.
  • Epidemiological studies and animal models suggest an association between high levels of dietary fat intake and an increased risk of breast cancer.
  • Cancer progression requires the development of metastasis, which is characterized by an increase in cell motility and invasion.
  • A similar process takes place during tumor progression, when carcinoma cells stably or transiently lose epithelial polarities and acquire a mesenchymal phenotype.
  • However, the role of AA on the EMT process in human mammary epithelial cells remains to be studied.
  • In conclusion, our results demonstrate, for the first time, that AA promotes an epithelial-to-mesenchymal-like transition in MCF10A human mammary non-tumorigenic epithelial cells.
  • [MeSH-major] Arachidonic Acid / metabolism. Cell Transdifferentiation / physiology. Epithelial Cells / pathology. Mammary Glands, Human / pathology. Signal Transduction / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20207443.001).
  • [ISSN] 1618-1298
  • [Journal-full-title] European journal of cell biology
  • [ISO-abbreviation] Eur. J. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 27YG812J1I / Arachidonic Acid
  •  go-up   go-down


84. Pedersen TX, Pennington CJ, Almholt K, Christensen IJ, Nielsen BS, Edwards DR, Rømer J, Danø K, Johnsen M: Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis; 2005 Jul;26(7):1233-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas.
  • Based on qualitative in situ hybridization studies in human cancer tissue, a range of components involved in proteolysis appear to be expressed by stromal cells rather than cancer cells.
  • We have now used laser capture microdissection and real-time PCR to quantify the mRNA expression of components of matrix-degrading proteolytic systems in cancer and stromal areas of mouse mammary tumors genetically induced by the polyoma virus middle T (PyMT) antigen.
  • Statistical analyses indicated that the quantitative expression patterns observed in cancer and stromal cells isolated from individual tumors from different PyMT mice are quite reproducible.
  • The methodology described in this study provides excellent tools to study the possible interactions between cancer and stromal cells during the development of breast cancer, and the results suggest that stromal cells are involved in carcinogenesis and tumor progression, which may have important implications for the biology and therapy of cancer.
  • [MeSH-major] Carcinoma / genetics. Mammary Neoplasms, Animal / genetics. Peptide Hydrolases / biosynthesis

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15760918.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.- / Peptide Hydrolases
  •  go-up   go-down


85. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, Warbritton AR, Latendresse JR, Kovalchuk I, Beland FA, Pogribny IP: Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle; 2007 Aug 15;6(16):2010-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast cancer is the most common malignancy in women continuing to rise worldwide.
  • Breast cancer emerges through a multi-step process, encompassing progressive changes from a normal cell to hyperplasia (with and without atypia), carcinoma in situ, invasive carcinoma, and metastasis.
  • In the current study, we analyzed the morphological changes and alterations of DNA methylation, histone methylation and microRNA expression during estradiol-17beta (E(2))-induced mammary carcinogenesis in female August Copenhagen Irish (ACI) rats.
  • E(2)-induced breast carcinogenesis in ACI rats provides a physiologically relevant and genetically defined animal model for studying human sporadic breast cancer.
  • The pattern of morphological changes in mammary glands during E(2)-induced carcinogenesis was characterized by transition from normal appearing alveolar and ductular hyperplasia to focal hyperplastic areas of atypical glands and ducts accompanied by a rapid and sustained loss of global DNA methylation, LINE-1 hypomethylation, loss of histone H3 lysine 9 and histone H4 lysine 20 trimethylation, and altered microRNAs expression.
  • More importantly, these alterations in the mammary tissue occurred after six weeks of E(2)-treatment, whereas the atypical hyperplasia, which represents a putative precursor lesion to mammary carcinoma in this model, was detected only after twelve weeks of exposure, demonstrating clearly that these events are directly associated with the effects of E(2) and are not a consequence of the preexisting preneoplastic lesions.
  • The results of this study show that deregulation of cellular epigenetic processes plays a crucial role in the mechanism of E(2)-induced mammary carcinogenesis in ACI rats, especially in the tumor initiation process.
  • [MeSH-major] DNA Methylation / drug effects. Estrogens / toxicity. Histones / metabolism. Mammary Neoplasms, Experimental / chemically induced. MicroRNAs / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17700064.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Histones; 0 / MicroRNAs; 4TI98Z838E / Estradiol; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase
  •  go-up   go-down


86. Burch S, Bisland SK, Bogaards A, Yee AJ, Whyne CM, Finkelstein JA, Wilson BC: Photodynamic therapy for the treatment of vertebral metastases in a rat model of human breast carcinoma. J Orthop Res; 2005 Sep;23(5):995-1003
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for the treatment of vertebral metastases in a rat model of human breast carcinoma.
  • Intracardiac injection of human MT-1 breast cancer cells was performed in athymic rats.
  • [MeSH-major] Mammary Neoplasms, Experimental / pathology. Phytotherapy. Spinal Neoplasms / drug therapy. Spinal Neoplasms / secondary
  • [MeSH-minor] Animals. Disease Models, Animal. Female. Humans. Immunohistochemistry. Luminescent Measurements. Neoplasm Transplantation. Rats. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140186.001).
  • [ISSN] 0736-0266
  • [Journal-full-title] Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  • [ISO-abbreviation] J. Orthop. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Becks L, Prince M, Burson H, Christophe C, Broadway M, Itoh K, Yamamoto M, Mathis M, Orchard E, Shi R, McLarty J, Pruitt K, Zhang S, Kleiner-Hancock HE: Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene. BMC Cancer; 2010 Oct 08;10:540
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene.
  • BACKGROUND: Activation of nuclear factor erythroid 2-related factor (Nrf2), which belongs to the basic leucine zipper transcription factor family, is a strategy for cancer chemopreventive phytochemicals.
  • We hypothesized that (1) the citrus coumarin auraptene may suppress premalignant mammary lesions via activation of Nrf2/ARE, and (2) that Nrf2 knockout (KO) mice would be more susceptible to mammary carcinogenesis.
  • METHODS: Premalignant lesions and mammary carcinomas were induced by medroxyprogesterone acetate and 7,12-dimethylbenz[a]anthracene treatment.
  • In the KO mice, there was a dramatic increase in mammary carcinoma growth rate, size, and weight.
  • Although there was no difference in overall survival, the KO mice had significantly lower mammary tumor-free survival.
  • Also, in the KO mammary carcinomas, the active forms of NF-κB and β-catenin were increased ~2-fold whereas no differences in oxidized proteins were observed.
  • CONCLUSIONS: We report, for the first time, that there was no apparent difference in the formation of premalignant lesions, but rather, the KO mice exhibited rapid, aggressive mammary carcinoma progression.

  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Chem. 2006 Oct-Nov;387(10-11):1329-35 [17081103.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Acta Pharmacol Sin. 2007 Sep;28(9):1409-21 [17723174.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1784-94 [17726138.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 3;362(4):816-21 [17822677.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1303-9 [18316592.001]
  • [Cites] Carcinogenesis. 2008 Jun;29(6):1235-43 [18413364.001]
  • [Cites] Med Chem. 2008 Sep;4(5):473-81 [18782044.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7975-84 [18829555.001]
  • [Cites] Pharmacol Res. 2008 Nov-Dec;58(5-6):262-70 [18838122.001]
  • [Cites] Gut. 2009 Jan;58(1):5-15 [18664505.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Aug;1(3):153-5 [19138949.001]
  • [Cites] Rev Med Chir Soc Med Nat Iasi. 2008 Apr-Jun;112(2):432-6 [19295016.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2966-72 [19339271.001]
  • [Cites] Toxicol Lett. 2009 Mar 28;185(3):180-6 [19150646.001]
  • [Cites] Carcinogenesis. 2009 Jun;30(6):1024-31 [19386581.001]
  • [Cites] Indian J Cancer. 2009 Jul-Sep;46(3):194-202 [19574670.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Comp Med. 2009 Jun;59(3):234-41 [19619413.001]
  • [Cites] BMC Cancer. 2009;9:259 [19640308.001]
  • [Cites] Curr Drug Metab. 2009 Jul;10(6):595-616 [19702535.001]
  • [Cites] Antioxid Redox Signal. 2009 May;11(5):949-62 [19123792.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 Apr 1;244(1):66-76 [19732782.001]
  • [Cites] Carcinogenesis. 2010 May;31(5):871-9 [19825967.001]
  • [Cites] Apoptosis. 2010 Jun;15(6):738-51 [20376563.001]
  • [Cites] Antioxid Redox Signal. 2010 Dec 1;13(11):1713-48 [20446772.001]
  • [Cites] Carcinogenesis. 2001 Jan;22(1):73-82 [11159744.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8 [14668450.001]
  • [Cites] Methods Enzymol. 1981;77:398-405 [7329316.001]
  • [Cites] Cancer Res. 1987 Aug 15;47(16):4271-7 [2886217.001]
  • [Cites] Cancer Res. 1990 Apr 15;50(8):2251-5 [2317812.001]
  • [Cites] Carcinogenesis. 1990 Oct;11(10):1849-55 [2119909.001]
  • [Cites] Methods Enzymol. 1990;186:464-78 [1978225.001]
  • [Cites] Carcinogenesis. 1996 Sep;17(9):2069-72 [8824536.001]
  • [Cites] Mol Carcinog. 1998 Jun;22(2):73-83 [9655251.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 17;91(4):347-54 [10050868.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):8028-33 [16140977.001]
  • [Cites] Org Biomol Chem. 2006 Apr 21;4(8):1604-10 [16604230.001]
  • [Cites] Nat Cell Biol. 2006 May;8(5):501-8 [16604061.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1204-13 [16387742.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):63-78 [16675129.001]
  • [Cites] FEBS Lett. 2006 Dec 11;580(28-29):6596-602 [17113580.001]
  • (PMID = 20932318.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NIH HHS / OD / R25 OD010954; United States / NCI NIH HHS / CA / 1K22CA102005-01A2; United States / NCRR NIH HHS / RR / R25RR026019
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coumarins; 0 / NF-E2-Related Factor 2; 0 / Nfe2l2 protein, mouse; 495-02-3 / aurapten; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ PMC2964634
  •  go-up   go-down


88. Peduto L, Reuter VE, Sehara-Fujisawa A, Shaffer DR, Scher HI, Blobel CP: ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. Oncogene; 2006 Aug 31;25(39):5462-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression.
  • Here, we describe the identification of ADAM12 (a disintegrin and metalloprotease 12) as a novel marker for a subpopulation of stromal cells that are adjacent to epithelial tumor cells in three mouse carcinoma models (models for prostate, breast and colon cancer).
  • Moreover, we show that ADAM12 is essential for tumor development and progression in the W10 mouse model for prostate cancer.
  • These results suggest that ADAM12 might be a useful marker for stromal cells in mouse tumors that are likely to participate in stromal/tumor cell crosstalk, and that ADAM12 is a potential target for design of drugs that prevent carcinoma growth.
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Division / drug effects. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Intestinal Neoplasms / genetics. Male. Mammary Neoplasms, Animal / genetics. Mice

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607276.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / C06-RR12538-01; United States / NIGMS NIH HHS / GM / GM64750
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / Adam12 protein, mouse
  •  go-up   go-down


89. Fermento ME, Gandini NA, Lang CA, Perez JE, Maturi HV, Curino AC, Facchinetti MM: Intracellular distribution of p300 and its differential recruitment to aggresomes in breast cancer. Exp Mol Pathol; 2010 Apr;88(2):256-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracellular distribution of p300 and its differential recruitment to aggresomes in breast cancer.
  • As a step towards determining the functional relevance of p300 intracellular redistribution in mammary cancer, we aimed at studying p300 localization in two different animal models of mammary carcinoma as well as in human primary breast carcinoma samples.
  • Analysis of p300 protein levels showed stronger expression in tumor epithelia than in normal mammary gland.
  • Furthermore, cytoplasmic p300 was found in tumor epithelia whereas nuclear localization was observed in normal mammary glands in both animal models and in non-malignant adjacent areas of human breast cancer specimens.
  • Interestingly, proteasomal inhibition induced p300 redistribution to perinuclear inclusion bodies in tumor but not in normal mammary gland-derived cells.
  • Taken together, these findings show that both the localization of p300 and the recruitment to aggresomes differ between mammary tumors and normal mammary glands, and suggest that the formation of these inclusions could be a potential target for therapeutic intervention.
  • [MeSH-minor] Adenocarcinoma / genetics. Animals. Blotting, Western. Cell Line, Tumor. Cytoplasm / metabolism. Cytoplasm / pathology. Female. Humans. Immunohistochemistry. Inclusion Bodies / metabolism. Inclusion Bodies / pathology. Mammary Glands, Animal / metabolism. Mammary Neoplasms, Animal / genetics. Mice. Mice, Transgenic. Proteasome Endopeptidase Complex / genetics. Proteasome Endopeptidase Complex / metabolism. Reference Values. Transcription, Genetic. Ubiquitin / metabolism. Vimentin / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [RetractionIn] Exp Mol Pathol. 2013 Apr;94(2):418 [23616987.001]
  • (PMID = 20097195.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ubiquitin; 0 / Vimentin; EC 2.3.1.48 / E1A-Associated p300 Protein; EC 2.3.1.48 / EP300 protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


90. Lagana A, Goetz JG, Cheung P, Raz A, Dennis JW, Nabi IR: Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol Cell Biol; 2006 Apr;26(8):3181-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein we report that fibronectin fibrillogenesis and fibronectin-dependent cell spreading are deficient in Mgat5(-/-) mammary epithelial tumor cells and inhibited in Mgat5(+/+) cells by blocking Golgi N-glycan processing with swainsonine or by competitive inhibition of galectin binding.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6239-45 [10626818.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):37266-77 [16105842.001]
  • [Cites] Nat Med. 2000 Mar;6(3):306-12 [10700233.001]
  • [Cites] J Cell Biol. 2000 Mar 6;148(5):1075-90 [10704455.001]
  • [Cites] Nat Cell Biol. 2000 Apr;2(4):191-6 [10783236.001]
  • [Cites] J Cell Sci. 2000 Jul;113 ( Pt 13):2385-97 [10852818.001]
  • [Cites] Glycobiology. 2000 Nov;10(11):1201-8 [11087712.001]
  • [Cites] J Cell Biol. 2000 Dec 11;151(6):1235-46 [11121438.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Apr;127(4):231-6 [11315257.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):31285-95 [11371555.001]
  • [Cites] J Cell Sci. 2001 Oct;114(Pt 20):3583-90 [11707510.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Nov;2(11):793-805 [11715046.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Dec 14;289(4):845-50 [11735123.001]
  • [Cites] J Biol Chem. 2002 Mar 15;277(11):9405-14 [11756413.001]
  • [Cites] Nat Cell Biol. 2002 Apr;4(4):E65-8 [11944032.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):15819-27 [11839755.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19703-8 [11912200.001]
  • [Cites] Biochemistry. 2002 Jul 23;41(29):9063-9 [12119020.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] J Cell Biol. 2002 Nov 25;159(4):695-705 [12446745.001]
  • [Cites] Curr Opin Struct Biol. 2002 Oct;12(5):616-23 [12464313.001]
  • [Cites] J Cell Sci. 2003 Aug 15;116(Pt 16):3269-76 [12857786.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 24;310(3):1010-6 [14550305.001]
  • [Cites] J Cell Sci. 2004 Jan 15;117(Pt 2):177-87 [